PTGX


Line plots across dimensions of each concept
Line plots across concepts
Tables

Table of contents



us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

us-gaap:EarningsPerShareBasicAndDiluted

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:GainsLossesOnExtinguishmentOfDebt

us-gaap:GeneralAndAdministrativeExpense

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

us-gaap:IncomeTaxExpenseBenefit

us-gaap:InterestExpense

us-gaap:NetIncomeLoss
us-gaap:StatementEquityComponents

us-gaap:OperatingExpenses

us-gaap:OperatingIncomeLoss

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:ProfitLoss

us-gaap:ResearchAndDevelopmentExpense
us-gaap:ProductOrService, us-gaap:Range, us-gaap:StatementScenario
us-gaap:CounterpartyName, us-gaap:ProductOrService
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

us-gaap:Assets

us-gaap:Liabilities

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents

us-gaap:AssetsCurrent

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:MarketableSecuritiesCurrent

us-gaap:PrepaidExpenseAndOtherAssetsCurrent

us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

us-gaap:PropertyPlantAndEquipmentNet
us-gaap:StatementGeographical

us-gaap:OperatingLeaseRightOfUseAsset

us-gaap:AccountsPayableCurrent

us-gaap:AccruedLiabilitiesCurrent

us-gaap:ContractWithCustomerLiabilityCurrent
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:LiabilitiesCurrent

us-gaap:OperatingLeaseLiabilityCurrent

us-gaap:OtherAccruedLiabilitiesCurrent

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour

us-gaap:OperatingLeaseLiability

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapitalCommonStock

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:StockIssuedDuringPeriodValueNewIssues
us-gaap:StatementEquityComponents
us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock
us-gaap:SubsidiarySaleOfStock

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
us-gaap:StatementEquityComponents

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:DepreciationDepletionAndAmortization

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetIncomeLoss
us-gaap:StatementEquityComponents

us-gaap:ProfitLoss

us-gaap:ShareBasedCompensation

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:EffectiveIncomeTaxRateContinuingOperations

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

us-gaap:UnrecognizedTaxBenefits

us-gaap:DeferredTaxAssetsValuationAllowance

ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName, us-gaap:ProductOrService
ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement
us-gaap:ProductOrService
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
ptgx:ContractWithCustomerAssetAdditions
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
ptgx:ContractWithCustomerAssetDeduction
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
ptgx:ContractWithCustomerAssetRelatedPartyAdditions
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
ptgx:ContractWithCustomerLiabilityAdditions
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
ptgx:ContractWithCustomerLiabilityDeduction
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
ptgx:DueToRelatedPartyAdditions
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
ptgx:DueToRelatedPartyDeductions

ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants

ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo

ptgx:IncreaseDecreaseInOperatingLeaseLiability
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement
ptgx:LicenseAndCollaborationAgreementMaximumCostThatCanBeIncurred

ptgx:OperatingLeaseRightOfUseAssetAmortization

ptgx:PotentialQualifiedDiscountFederalIncomeTaxCredit
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement
ptgx:ReducedMilestonePaymentAmount
ptgx:RevenueSource
ptgx:ResearchAndDevelopmentExpensesReduction
us-gaap:IncomeTaxAuthorityName
us-gaap:Range, us-gaap:IncomeTaxAuthorityName
ptgx:ResearchAndDevelopmentTaxIncentiveRevenueCriteria

ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract
us-gaap:CounterpartyName
ptgx:SaleOfStockValueOfSharesAuthorized
us-gaap:CounterpartyName, us-gaap:SubsequentEventType
us-gaap:SubsequentEventType, us-gaap:SubsidiarySaleOfStock
us-gaap:SubsidiarySaleOfStock

ptgx:SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits
us-gaap:StatementEquityComponents

us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments

us-gaap:CapitalExpendituresIncurredButNotYetPaid

us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
us-gaap:CounterpartyName, us-gaap:ProductOrService
us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice

us-gaap:ContractWithCustomerLiabilityRevenueRecognized
us-gaap:CounterpartyName, us-gaap:ProductOrService
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction

us-gaap:DefinedContributionPlanAdministrativeExpenses

us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch

us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount

us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:IncomeTaxCreditsAndAdjustments

us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties

us-gaap:IncreaseDecreaseInAccountsPayableTrade

us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties

us-gaap:IncreaseDecreaseInContractWithCustomerLiability

us-gaap:IncreaseDecreaseInIncomeTaxesReceivable

us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

us-gaap:InvestmentIncomeInterest
us-gaap:CounterpartyName
us-gaap:LossContingencyDamagesSoughtValue
us-gaap:CounterpartyName, us-gaap:Range, us-gaap:StatementScenario
us-gaap:CounterpartyName, us-gaap:StatementScenario

us-gaap:OperatingLeasePayments

us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
us-gaap:StatementEquityComponents

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

us-gaap:PaymentsOfDebtIssuanceCosts

us-gaap:PaymentsOfStockIssuanceCosts

us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt

us-gaap:ProceedsFromDebtNetOfIssuanceCosts

us-gaap:ProceedsFromIssuanceOfCommonStock
us-gaap:StatementEquityComponents, us-gaap:SubsequentEventType, us-gaap:SubsidiarySaleOfStock
us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock

us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions

us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
us-gaap:SubsidiarySaleOfStock
us-gaap:SaleOfStockConsiderationReceivedOnTransaction
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
us-gaap:PlanName
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap:PlanName
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
us-gaap:PlanName

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap:AwardType
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
us-gaap:PlanName
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
us-gaap:BalanceSheetLocation, us-gaap:SubsidiarySaleOfStock
us-gaap:StockIssued1

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
us-gaap:StatementEquityComponents

ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent
us-gaap:ProductOrService, us-gaap:Range, us-gaap:StatementScenario, us-gaap:TypeOfArrangement
ptgx:AdditionalPaymentObligationToFormerCollaborationPartner

ptgx:CashCashEquivalentsAndMarketableSecuritiesCarryingValue

ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
us-gaap:CashAndCashEquivalents
us-gaap:InvestmentType

ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
us-gaap:CashAndCashEquivalents
us-gaap:InvestmentType

ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
us-gaap:CashAndCashEquivalents
us-gaap:InvestmentType

ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
us-gaap:CashAndCashEquivalents
us-gaap:InvestmentType

ptgx:DeferredTaxAssetsOperatingLeaseLiability

ptgx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement
ptgx:LicenseAndCollaborationAgreementDevelopmentExpensesObligationEliminated
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement
ptgx:LicenseAndCollaborationAgreementPercentageOfDevelopmentExpensesObligationEliminated
us-gaap:SubsequentEventType
ptgx:OperatingLeaseAdditionalBaseRent
us-gaap:IncomeTaxAuthority
ptgx:OperatingLossCarryforwardsNoExpiration
us-gaap:CounterpartyName, us-gaap:StatementScenario
ptgx:PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation
us-gaap:ProductOrService, us-gaap:Range, us-gaap:TypeOfArrangement
ptgx:PotentialMilestonePaymentsOnContractualObligation
us-gaap:CounterpartyName, us-gaap:StatementScenario
ptgx:PotentialSalesMilestonePaymentsOnContractualObligation

ptgx:PrepaidManufacturingOfClinicalMaterials
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
ptgx:ReimbursementForServicesPerformed
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement
ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

us-gaap:AccruedEmployeeBenefitsCurrent

us-gaap:AccruedProfessionalFeesCurrent
us-gaap:SubsequentEventType
us-gaap:AreaOfLand
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:AssetsFairValueDisclosure
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType
us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType

us-gaap:CashEquivalentsAtCarryingValue
us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock
us-gaap:CommonStockValueOutstanding
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
us-gaap:ContractWithCustomerAssetNet

us-gaap:ContractWithCustomerLiabilityNoncurrent

us-gaap:DebtInstrumentInterestRateEffectivePercentage

us-gaap:DeferredIncomeTaxLiabilities

us-gaap:DeferredTaxAssetsGross

us-gaap:DeferredTaxAssetsOperatingLossCarryforwards

us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment

us-gaap:DeferredTaxAssetsTaxCreditCarryforwards

us-gaap:DeferredTaxLiabilitiesLeasingArrangements

us-gaap:DueFromRelatedPartiesCurrent

us-gaap:DueToRelatedPartiesCurrent
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
ptgx:RevenueSource
us-gaap:GrantsReceivable

us-gaap:IncomeTaxesReceivable
us-gaap:IncomeTaxAuthority, us-gaap:IncomeTaxAuthorityName

us-gaap:InterestPayableCurrent

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

us-gaap:MarketableSecuritiesNoncurrent
us-gaap:IncomeTaxAuthority
us-gaap:OperatingLossCarryforwards
us-gaap:IncomeTaxAuthorityName

us-gaap:OtherAccountsPayableAndAccruedLiabilities

us-gaap:OtherPrepaidExpenseCurrent

us-gaap:OtherReceivablesNetCurrent

us-gaap:PrepaidInsurance

us-gaap:RestrictedCashNoncurrent
us-gaap:CreditFacility

us-gaap:RevenueRemainingPerformanceObligation
us-gaap:CounterpartyName, us-gaap:ProductOrService
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
us-gaap:PlanName

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
us-gaap:StatementEquityComponents
us-gaap:SharesIssuedPricePerShare
us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock
us-gaap:IncomeTaxAuthority, us-gaap:TaxCreditCarryforward
us-gaap:TaxCreditCarryforwardAmount
us-gaap:IncomeTaxAuthorityName, us-gaap:TaxCreditCarryforward
us-gaap:SubsidiarySaleOfStock
us-gaap:WarrantsAndRightsOutstanding

Plots across concepts


Expenses
Other Nonoperating Income Expense
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Property Plant And Equipment Net
Current Assets
Prepaid Expense And Other Assets Current
NonCurrent Assets
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
Property Plant And Equipment Net
Liabilities
Operating Lease Liability
Current Liabilities
Other Accrued Liabilities Current
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Income Loss
NetCashProvidedByUsedInOperatingActivities
Net Income Loss
NetCashProvidedByUsedInInvestingActivities
Payments To Acquire Property Plant And Equipment
NetCashProvidedByUsedInFinancingActivities
Repayments Of Long Term Debt
OperatingLeaseLiability
Operating Lease Liability Current
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Due Year Four

Tables

  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted █▁44.86463744.224169NA37.38688132.79969124.662779
us-gaap:EarningsPerShareBasicAndDiluted ▅▆▆█▅▁-0.69-0.54-0.47-0.21-0.59-1.18
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:AllocatedShareBasedCompensationExpense █▄▁▁▁▁3.9362.661.9671.8881.9962.013
us-gaap:ComprehensiveIncomeNetOfTax ▁▃▅█▄▂-30.868-24.059-18.77-7.643-19.736-29.152
us-gaap:GainsLossesOnExtinguishmentOfDebt NANA0.00.0-0.585NA
us-gaap:GeneralAndAdministrativeExpense █▆▄▄▂▁6.7155.9654.9944.8914.1773.863
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest ▁▃▅█▅▁-30.842-23.998-18.886-7.763-18.292-30.803
us-gaap:IncomeTaxExpenseBenefit NANA0.00.01.129-1.629
us-gaap:InterestExpense NANA0.1270.0190.209NA
us-gaap:NetIncomeLoss ▁▃▅█▄▂-30.842-23.998-18.886-7.763-19.421-29.174
 us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents us-gaap:RetainedEarnings▁▃▅█▄▂-30.842-23.998-18.886-7.763-19.421-29.174
us-gaap:OperatingExpenses █▆▃▁▃▂33.14730.2124.4820.88624.43423.218
us-gaap:OperatingIncomeLoss ▁▃▅█▅▁-30.882-24.021-18.83-7.772-18.217-31.407
us-gaap:OtherNonoperatingIncomeExpense ▁▁▂▁█▁-0.057-0.079-0.009-0.0590.512-0.037
us-gaap:ProfitLoss ▁▃▅█▄▂-30.842-23.998-18.886-7.763-19.421-29.174
us-gaap:ResearchAndDevelopmentExpense █▇▃▁▄▃26.43224.24519.48615.99520.25719.355
 us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax us-gaap:CounterpartyName,us-gaap:ProductOrService ptgx:JanssenBiotechInc,us-gaap:FinancialServiceOther▃█▇▇▇▁0.20.60.50.50.50.0
 us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax us-gaap:CounterpartyName,us-gaap:ProductOrService,us-gaap:TypeOfArrangement ptgx:JanssenBiotechInc,ptgx:LicenseAndCollaborativeRevenue,ptgx:EstimatedVariableConsiderationNA7.5NA-8.00.2NA
 us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax us-gaap:CounterpartyName,us-gaap:ProductOrService,us-gaap:TypeOfArrangement ptgx:JanssenBiotechInc,ptgx:LicenseAndCollaborativeRevenue,ptgx:PhaseTwoClinicalTrialNA17.9-0.50.00.1NA
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:Assets █▅▆▃▃▁404.232298.072324.468217.32224.98148.105
us-gaap:Liabilities ▃▁▃▄▆█46.78538.73844.86247.7357.49563.789
us-gaap:LiabilitiesAndStockholdersEquity █▅▆▃▃▁404.232298.072324.468217.32224.98148.105
us-gaap:StockholdersEquity █▅▆▃▃▁357.447259.334279.606169.59167.48584.316
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:AssetsCurrent █▅▆▃▃▁371.818285.508315.606204.151217.466137.32
us-gaap:CashAndCashEquivalentsAtCarryingValue █▂▄▂▅▁192.41283.0117.35883.625146.24271.143
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents █▂▄▂▅▁192.63783.225117.81884.085146.70271.603
us-gaap:MarketableSecuritiesCurrent ▇██▄▁▁161.868190.476188.451110.34962.42354.958
us-gaap:PrepaidExpenseAndOtherAssetsCurrent █▄▄▆▃▁7.6836.2136.2776.8435.5184.899
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:PropertyPlantAndEquipmentGross NANA4.935NANA4.075
 us-gaap:PropertyPlantAndEquipmentGross us-gaap:PropertyPlantAndEquipmentByType ptgx:FurnitureAndComputerEquipmentNANA0.648NANA0.467
 us-gaap:PropertyPlantAndEquipmentGross us-gaap:PropertyPlantAndEquipmentByType ptgx:LaboratoryEquipmentNANA3.539NANA2.869
 us-gaap:PropertyPlantAndEquipmentGross us-gaap:PropertyPlantAndEquipmentByType us-gaap:LeaseholdImprovementsNANA0.748NANA0.739
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment NANA3.473NANA2.383
us-gaap:PropertyPlantAndEquipmentNet █▁▂▂▄▇1.7181.4321.4621.4591.5531.692
us-gaap:OperatingLeaseRightOfUseAsset ▁▂▃▄▅█4.3494.6534.955.2355.5116.539
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:AccountsPayableCurrent █▁▁▁▁▁7.9052.7323.0752.7972.8552.787
us-gaap:AccruedLiabilitiesCurrent █▆▇▅▃▁20.09617.6818.49815.51812.91710.845
us-gaap:ContractWithCustomerLiabilityCurrent ▁▃▇███2.0095.76814.47716.76517.2317.717
us-gaap:LiabilitiesCurrent █▂▆▅▂▁42.97334.51540.24138.56335.3633.323
us-gaap:OperatingLeaseLiabilityCurrent █▇▆▅▄▁1.5671.5121.4591.4061.3551.164
us-gaap:OtherAccruedLiabilitiesCurrent █▆▂▃▁▁0.5110.3980.0820.1280.0360.022
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:OtherLiabilitiesNoncurrent ▁▁▁█0.1210.1210.1210.17NANA
us-gaap:OperatingLeaseLiabilityNoncurrent ▁▂▃▄▅█3.6914.1024.54.8855.2596.616
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo NANA2.059NANANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree NANA2.121NANANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour NANA0.895NANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:StockholdersEquity █▅▆▃▃▁357.447259.334279.606169.59167.48584.316
us-gaap:AdditionalPaidInCapitalCommonStock █▆▆▄▄▁696.157567.176563.389434.603424.855268.234
us-gaap:RetainedEarningsAccumulatedDeficit ▁▂▃▄▅█-338.651-307.809-283.811-264.925-257.162-183.751
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax ▅▆█▅▁▂-0.059-0.0330.028-0.088-0.208-0.167
us-gaap:StockIssuedDuringPeriodValueNewIssues 123.798NA107.646-0.003105.33110.543
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue █▄▁▁▁▁3.9362.661.9671.8881.9962.013
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:NetCashProvidedByUsedInOperatingActivities ▂▁▃▄▃█-23.7-28.756-18.867-16.287-21.4823.67
us-gaap:NetCashProvidedByUsedInInvestingActivities █▇▁▃▇▆7.773-6.793-74.402-54.122-5.171-13.225
us-gaap:NetCashProvidedByUsedInFinancingActivities █▁█▁▇▂125.390.979126.9817.669112.57710.63
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect █▂▅▁▇▄109.412-34.59333.733-62.61786.0271.066
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:DepreciationDepletionAndAmortization ▃▂▄▃█▁0.1850.180.1880.1820.2020.176
us-gaap:NetCashProvidedByUsedInOperatingActivities ▂▁▃▄▃█-23.7-28.756-18.867-16.287-21.4823.67
us-gaap:NetIncomeLoss ▁▃▅█▄▂-30.842-23.998-18.886-7.763-19.421-29.174
 us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents us-gaap:RetainedEarnings▁▃▅█▄▂-30.842-23.998-18.886-7.763-19.421-29.174
us-gaap:ProfitLoss ▁▃▅█▄▂-30.842-23.998-18.886-7.763-19.421-29.174
us-gaap:ShareBasedCompensation █▄▁▁▁▁3.9362.661.9671.8881.9962.013
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:NetCashProvidedByUsedInInvestingActivities █▇▁▃▇▆7.773-6.793-74.402-54.122-5.171-13.225
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ▅▂▁▁▁█0.50.140.1250.0750.1330.892
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
us-gaap:NetCashProvidedByUsedInFinancingActivities █▁█▁▇▂125.390.979126.9817.669112.57710.63
  2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30

Weighted Average Number Of Share Outstanding Basic And Diluted

us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted


Weighted
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-09-302016-06-302016-03-312015-09-302015-06-30
Value44443732272624242221211616168.4831890.383910.28780.2724090.233531
Percentage of WeightedAverageNumberOfShareOutstandingBasicAndDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Basic And Diluted

us-gaap:EarningsPerShareBasicAndDiluted

us-gaap:EarningsPerShareBasicAndDiluted


Earnings
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value-0.69-0.54-0.47-0.21-0.59-0.72-0.63-0.61-1.18-0.58-0.57-0.38-0.41-0.36-0.15-0.29-0.89-0.84-0.67-0.87-19.07-40.96-20.31-12.79-13.78-11.75
Percentage of EarningsPerShareBasicAndDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Allocated Share Based Compensation Expense

us-gaap:AllocatedShareBasedCompensationExpense

us-gaap:AllocatedShareBasedCompensationExpense


Allocated
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-30
Value3936000.02660000.01967000.01888000.01996000.02048000.02160000.02201000.02013000.01979000.02072000.02017000.01645000.01185000.01189000.01207000.01001000.0843000.01520000.0448000.0106000.056000.037000.022000.021000.0
Percentage of AllocatedShareBasedCompensationExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.013.70.00.00.00.00.00.00.00.00.0

us-gaap:AllocatedShareBasedCompensationExpense us-gaap:IncomeStatementLocation

us-gaap:GeneralAndAdministrativeExpense


Allocated
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-30
Value1781000.01185000.0944000.0882000.0970000.0982000.01047000.01064000.01036000.0857000.01072000.0971000.0808000.0644000.0580000.0607000.0525000.0484000.0800000.0163000.060000.027000.022000.014000.013000.0
Percentage of AllocatedShareBasedCompensationExpense45.244.548.046.748.647.948.548.351.543.351.748.149.154.348.850.352.457.452.636.456.648.259.563.661.9
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.06.90.00.00.00.00.00.00.00.00.0
Percentage of Revenues us-gaap:GeneralAndAdministrativeExpense0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:ResearchAndDevelopmentExpense


Allocated
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-30
Value2155000.01475000.01023000.01006000.01026000.01066000.01113000.01137000.0977000.01122000.01000000.01046000.0837000.0541000.0609000.0600000.0476000.0359000.0720000.0285000.046000.029000.015000.08000.08000.0
Percentage of AllocatedShareBasedCompensationExpense54.855.552.053.351.452.151.551.748.556.748.351.950.945.751.249.747.642.647.463.643.451.840.536.438.1
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.06.80.00.00.00.00.00.00.00.00.0
Percentage of Revenues us-gaap:ResearchAndDevelopmentExpense0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Comprehensive Income Net Of Tax

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:ComprehensiveIncomeNetOfTax


Comprehensive
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-30
Value-30868000.0-24059000.0-18770000.0-7643000.0-19736000.0-19752000.0-17568000.0-16396000.0-29152000.0-14059000.0-13995000.0-8752000.0-8677000.0-7727000.0-3158000.0-4728000.0-14954000.0-13878000.0-11469000.0-7008000.0-7103000.0-11740000.0-5282000.0-3620000.0-3245000.0
Percentage of ComprehensiveIncomeNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0-53.80.00.00.00.00.00.00.00.00.0

Gains Losses On Extinguishment Of Debt

us-gaap:GainsLossesOnExtinguishmentOfDebt

us-gaap:GainsLossesOnExtinguishmentOfDebt


Gains
Period End2020-12-312020-09-302020-06-30
Value00-585000.0
Percentage of GainsLossesOnExtinguishmentOfDebt0.00.0100.0
Percentage of Revenues0.00.00.0

General And Administrative Expense

us-gaap:GeneralAndAdministrativeExpense

us-gaap:GeneralAndAdministrativeExpense


General
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-30
Value6.7155.9654.9944.8914.1774.5764.1074.0153.8633.7643.5173.3613.1783.6423.0712.5933.1242.9912.5741.5771.3951.4150.8080.8630.786
Percentage of GeneralAndAdministrativeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.029.50.00.00.00.00.00.00.00.00.0

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest


Income
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value-30842000.0-23998000.0-18886000.0-7763000.0-18292000.0-19904000.0-16645000.0-16511000.0-30803000.0-13920000.0-14664000.0-8735000.0-8663000.0-7661000.0
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Income Tax Expense Benefit

us-gaap:IncomeTaxExpenseBenefit

us-gaap:IncomeTaxExpenseBenefit


Income
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value001129000.0176000.0856000.0-102000.0-1629000.0183000.0-799000.0000
Percentage of IncomeTaxExpenseBenefit0.00.0100.0100.0100.0100.0100.0100.0100.00.00.00.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.0

Interest Expense

us-gaap:InterestExpense

us-gaap:InterestExpense


Interest
Period End2020-12-312020-09-302020-06-302020-03-31
Value127000.019000.0209000.0243000.0
Percentage of InterestExpense100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.0

Net Income Loss

us-gaap:NetIncomeLoss

us-gaap:NetIncomeLoss


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value-30842000.0-23998000.0-18886000.0-7763000.0-19421000.0-20080000.0-17501000.0-16409000.0-29174000.0-14103000.0-13865000.0-8735000.0-8663000.0-7661000.0-3052000.0-4825000.0-14979000.0-14101000.0-11248000.0-7084000.0-7098000.0-11747000.0-5493000.0-3449000.0-3219000.0-2697000.0
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0-54.90.00.00.00.00.00.00.00.00.00.0

us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value-30842000.0-23998000.0-18886000.0-7763000.0-19421000.0-20080000.0-17501000.0-16409000.0-29174000.0-14103000.0-13865000.0-8735000.0-8663000.0-7661000.0
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Revenues us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Operating Expenses

us-gaap:OperatingExpenses

us-gaap:OperatingExpenses


Operating
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-30
Value333024202423202123161715201914131514117.1387.0917.045.0014.0213.083
Percentage of OperatingExpenses100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0156.70.00.00.00.00.00.00.00.00.0

Operating Income Loss

us-gaap:OperatingIncomeLoss

us-gaap:OperatingIncomeLoss


Operating
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value-30882000.0-24021000.0-18830000.0-7772000.0-18217000.0-19697000.0-17299000.0-17167000.0-31407000.0-14648000.0-15412000.0-9389000.0-9239000.0-8229000.0-3513000.0-4980000.0-15131000.0-14273000.0-11397000.0-7138000.0-7091000.0-7040000.0-5001000.0-4021000.0-3083000.0-2689000.0
Percentage of OperatingIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0-56.70.00.00.00.00.00.00.00.00.00.0

Other Nonoperating Income Expense

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:OtherNonoperatingIncomeExpense


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312017-12-312017-09-302017-06-302016-09-302016-06-30
Value-57000.0-79000.0-9000.0-59000.0512000.0-490000.0144000.0-106000.0-37000.0-3000.0-8000.0000-34000.0
Percentage of OtherNonoperatingIncomeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Profit Loss

us-gaap:ProfitLoss

us-gaap:ProfitLoss


Profit
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value-30842000.0-23998000.0-18886000.0-7763000.0-19421000.0-20080000.0-17501000.0-16409000.0-29174000.0-14103000.0-13865000.0-8735000.0-8663000.0-7661000.0-3052000.0-4825000.0-14979000.0-14101000.0
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0-54.90.00.0

Research And Development Expense

us-gaap:ResearchAndDevelopmentExpense

us-gaap:ResearchAndDevelopmentExpense


Research
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-30
Value2624191520181517191214121715111112118.8235.5615.6965.6254.1933.1582.297
Percentage of ResearchAndDevelopmentExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0127.20.00.00.00.00.00.00.00.00.0

us-gaap:ResearchAndDevelopmentExpense us-gaap:ProductOrService, us-gaap:Range, us-gaap:StatementScenario

ptgx:PhaseThreeClinicalTrailOfPtg300, srt:Maximum, us-gaap:ScenarioPlan


Research
Period End2021-06-302021-03-31
Value0.04.5
Percentage of ResearchAndDevelopmentExpense0.018.6
Percentage of Revenues0.00.0
Percentage of Revenues ptgx:PhaseThreeClinicalTrailOfPtg300 srt:Maximum us-gaap:ScenarioPlan0.00.0

ptgx:PhaseThreeClinicalTrailOfPtg300, srt:Minimum, us-gaap:ScenarioPlan


Research
Period End2021-06-302021-03-31
Value0.01.5
Percentage of ResearchAndDevelopmentExpense0.06.2
Percentage of Revenues0.00.0
Percentage of Revenues ptgx:PhaseThreeClinicalTrailOfPtg300 srt:Minimum us-gaap:ScenarioPlan0.00.0

ptgx:PhaseTwoBClinicalTrailOfPtg300, srt:Maximum, us-gaap:ScenarioPlan


Research
Period End2021-06-302021-03-31
Value0.03.0
Percentage of ResearchAndDevelopmentExpense0.012.4
Percentage of Revenues0.00.0
Percentage of Revenues ptgx:PhaseTwoBClinicalTrailOfPtg300 srt:Maximum us-gaap:ScenarioPlan0.00.0

ptgx:PhaseTwoBClinicalTrailOfPtg300, srt:Minimum, us-gaap:ScenarioPlan


Research
Period End2021-06-302021-03-31
Value0.01.0
Percentage of ResearchAndDevelopmentExpense0.04.1
Percentage of Revenues0.00.0
Percentage of Revenues ptgx:PhaseTwoBClinicalTrailOfPtg300 srt:Minimum us-gaap:ScenarioPlan0.00.0

Revenue From Contract With Customer Including Assessed Tax

us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax us-gaap:CounterpartyName, us-gaap:ProductOrService

us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax

ptgx:JanssenBiotechInc, us-gaap:FinancialServiceOther


Revenue
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302019-06-30
Value0.20.60.50.50.50.0
Percentage of RevenueFromContractWithCustomerIncludingAssessedTax100.0100.0100.0100.0100.00.0
Percentage of Revenues0.00.00.00.00.00.0
Percentage of Revenues ptgx:JanssenBiotechInc us-gaap:FinancialServiceOther0.00.00.00.00.00.0

us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

ptgx:JanssenBiotechInc, ptgx:LicenseAndCollaborativeRevenue, ptgx:EstimatedVariableConsideration


Revenue
Period End2021-03-312020-09-302020-06-302020-03-312019-09-30
Value7.5-8.00.21517
Percentage of RevenueFromContractWithCustomerIncludingAssessedTax1250.0-1600.040.00.00.0
Percentage of Revenues0.00.00.00.00.0
Percentage of Revenues ptgx:JanssenBiotechInc ptgx:LicenseAndCollaborativeRevenue ptgx:EstimatedVariableConsideration0.00.00.00.00.0

ptgx:JanssenBiotechInc, ptgx:LicenseAndCollaborativeRevenue, ptgx:PhaseTwoClinicalTrial


Revenue
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Value17-0.50.00.118-0.1
Percentage of RevenueFromContractWithCustomerIncludingAssessedTax2983.3-100.00.020.00.00.0
Percentage of Revenues0.00.00.00.00.00.0
Percentage of Revenues ptgx:JanssenBiotechInc ptgx:LicenseAndCollaborativeRevenue ptgx:PhaseTwoClinicalTrial0.00.00.00.00.00.0

Assets

us-gaap:Assets

us-gaap:Assets


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value4042983242172241341541541481321391481371491631107082931022414
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Liabilities

us-gaap:Liabilities

us-gaap:Liabilities


Liabilities
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302016-12-312016-09-302016-06-302015-12-31
Value463844475772745963312624293443529.4496.4355.3494.115.249
Percentage of Liabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets11.613.013.822.025.653.548.438.343.123.819.316.721.723.226.347.613.46.85.216.835.4

Liabilities And Stockholders Equity

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:LiabilitiesAndStockholdersEquity


Liabilities
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value4042983242172241341541541481321391481371491631107082931022414
Percentage of LiabilitiesAndStockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Stockholders Equity

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-312014-12-312013-12-31
Value357259279169167627995841001121231071141205761748797-46.204-27.4-12.621-1.394
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets88.487.086.278.074.446.551.661.756.976.280.783.378.376.873.752.486.690.693.294.8-188.5-184.60.00.0

us-gaap:StockholdersEquity us-gaap:StatementEquityComponents

us-gaap:AccumulatedOtherComprehensiveIncome


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value-0.059-0.0330.028-0.088-0.2080.107-0.221-0.154-0.167-0.189-0.233-0.103-0.086-0.072-0.006-0.245-0.102-0.1-0.046
Percentage of StockholdersEquity-0.0-0.00.0-0.1-0.10.2-0.3-0.2-0.2-0.2-0.2-0.1-0.1-0.1-0.0-0.30.40.83.3
Percentage of Assets-0.0-0.00.0-0.0-0.10.1-0.1-0.1-0.1-0.1-0.2-0.1-0.1-0.0-0.0-0.3-0.70.00.0
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AdditionalPaidInCapital


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value6965675634344243002972952682552532502252232221520.1180.0370.135
Percentage of StockholdersEquity194.8218.7201.5256.3253.7479.2372.5310.1318.1253.5225.1202.2209.6195.3184.2174.1-0.4-0.3-9.7
Percentage of Assets172.2190.3173.6200.0188.8222.6192.3191.2181.1193.3181.6168.4164.1150.0135.7162.10.80.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value-338.651-307.809-283.811-264.925-257.162-237.741-217.661-200.16-183.751-154.577-140.474-126.609-117.874-109.211-101.55-64.593-27.416-12.558-1.483
Percentage of StockholdersEquity-94.7-118.7-101.5-156.2-153.5-379.4-272.2-209.9-217.9-153.3-124.8-102.1-109.5-95.3-84.2-73.8100.199.5106.4
Percentage of Assets-83.8-103.3-87.5-121.9-114.3-176.2-140.5-129.4-124.1-116.9-100.7-85.1-85.7-73.2-62.0-68.7-184.70.00.0
Percentage of Assets us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Assets Current

us-gaap:AssetsCurrent

us-gaap:AssetsCurrent


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value371285315204217125145144137122137147136142150976967831022214
Percentage of AssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets92.095.897.393.996.793.493.893.192.793.098.699.199.095.392.288.598.181.788.699.491.495.7

Cash And Cash Equivalents At Carrying Value

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:CashAndCashEquivalentsAtCarryingValue


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302014-12-312013-12-31
Value192831178314660335071708287636910650109.517219613284.055163.3999.3248.46
Percentage of CashAndCashEquivalentsAtCarryingValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets47.627.836.238.565.044.621.332.548.053.059.058.746.546.664.845.614.711.522.493.456.20.027.30.00.00.00.0

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-312014-12-31
Value192831178414660335071708287647010650109.9772196134.0659.334
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets47.727.936.338.765.245.021.632.848.353.359.359.046.846.965.046.115.412.122.493.456.227.40.0

Marketable Securities Current

us-gaap:MarketableSecuritiesCurrent

us-gaap:MarketableSecuritiesCurrent


Marketable
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Value1611901881106257100875446
Percentage of MarketableSecuritiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets40.063.958.150.827.742.564.656.637.133.4

Prepaid Expense And Other Assets Current

us-gaap:PrepaidExpenseAndOtherAssetsCurrent

us-gaap:PrepaidExpenseAndOtherAssetsCurrent


Prepaid
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value7683000.06213000.06277000.06843000.05518000.04716000.05529000.04203000.04899000.03502000.02624000.03234000.02959000.02621000.03773000.02703000.01743000.01810000.03394000.01768000.0487000.01558000.0
Percentage of PrepaidExpenseAndOtherAssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.92.11.93.12.53.53.62.73.32.61.92.22.21.82.32.42.52.23.61.72.010.5

Property Plant And Equipment Gross

us-gaap:PropertyPlantAndEquipmentGross

us-gaap:PropertyPlantAndEquipmentGross


Property
Period End2020-12-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-312015-12-31
Value4935000.04322000.04293000.04075000.03755000.02938000.02473000.01875000.01640000.0
Percentage of PropertyPlantAndEquipmentGross100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.52.82.82.82.82.11.52.011.0

us-gaap:PropertyPlantAndEquipmentGross us-gaap:PropertyPlantAndEquipmentByType

ptgx:FurnitureAndComputerEquipment


Property
Period End2020-12-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-312015-12-31
Value648000.0512000.0487000.0467000.0383000.0338000.0270000.0163000.0140000.0
Percentage of PropertyPlantAndEquipmentGross13.111.811.311.510.211.510.98.78.5
Percentage of Assets0.20.30.30.30.30.20.20.20.9
Percentage of Assets ptgx:FurnitureAndComputerEquipment0.00.00.00.00.00.00.00.00.0

ptgx:LaboratoryEquipment


Property
Period End2020-12-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-312015-12-31
Value3539000.02947000.03006000.02869000.02702000.02533000.02177000.01650000.01452000.0
Percentage of PropertyPlantAndEquipmentGross71.768.270.070.472.086.288.088.088.5
Percentage of Assets1.11.91.91.92.01.81.31.89.8
Percentage of Assets ptgx:LaboratoryEquipment0.00.00.00.00.00.00.00.00.0

us-gaap:LeaseholdImprovements


Property
Period End2020-12-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-312015-12-31
Value748000.0863000.0800000.0739000.0670000.067000.026000.062000.048000.0
Percentage of PropertyPlantAndEquipmentGross15.220.018.618.117.82.31.13.32.9
Percentage of Assets0.20.60.50.50.50.00.00.10.3
Percentage of Assets us-gaap:LeaseholdImprovements0.00.00.00.00.00.00.00.00.0

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment


Accumulated
Period End2020-12-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-312015-12-31
Value3473000.02641000.02559000.02383000.02209000.02077000.01594000.01313000.01031000.0
Percentage of AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.11.71.71.61.71.51.01.46.9

Property Plant And Equipment Net

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:PropertyPlantAndEquipmentNet


Property
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value1718000.01432000.01462000.01459000.01553000.01603000.01681000.01734000.01692000.01546000.0861000.0904000.0912000.01001000.0879000.0945000.0903000.0641000.0562000.0564000.0599000.0609000.0
Percentage of PropertyPlantAndEquipmentNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.40.50.50.70.71.21.11.11.11.20.60.60.70.70.50.91.30.80.60.52.44.1

us-gaap:PropertyPlantAndEquipmentNet us-gaap:StatementGeographical

country:AU


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Value46000.037000.0200.01200.08000.051000.0
Percentage of PropertyPlantAndEquipmentNet3.12.20.00.11.48.4
Percentage of Assets0.00.00.00.00.00.3
Percentage of Assets country:AU0.00.00.00.00.00.0

Operating Lease Right Of Use Asset

us-gaap:OperatingLeaseRightOfUseAsset

us-gaap:OperatingLeaseRightOfUseAsset


Operating
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312019-01-01
Value4349000.04653000.04950000.05235000.05511000.05780000.06042000.06295000.06539000.06779000.07500000.0
Percentage of OperatingLeaseRightOfUseAsset100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.11.61.52.42.44.33.94.14.45.10.0

Accounts Payable Current

us-gaap:AccountsPayableCurrent

us-gaap:AccountsPayableCurrent


Accounts
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value7905000.02732000.03075000.02797000.02855000.03704000.02790000.01583000.02787000.06454000.05711000.04871000.02278000.01307000.01257000.02267000.02639000.01132000.01163000.02335000.01441000.01247000.0
Percentage of AccountsPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.00.90.91.31.32.71.81.01.94.94.13.31.70.90.82.13.71.41.22.35.98.4

Accrued Liabilities Current

us-gaap:AccruedLiabilitiesCurrent

us-gaap:AccruedLiabilitiesCurrent


Accrued
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value2017181512111210108.713111013109.5468.2416.7276.6475.2723.0142.6691.879
Percentage of AccruedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets5.05.95.77.15.78.68.06.87.36.68.07.19.66.95.87.59.58.05.62.910.912.7

Contract With Customer Liability Current

us-gaap:ContractWithCustomerLiabilityCurrent

us-gaap:ContractWithCustomerLiabilityCurrent


Contract
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value2.0095.768141617181716177.0018.2237.97132131
Percentage of ContractWithCustomerLiabilityCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.51.94.57.77.713.811.510.712.05.35.95.49.614.719.4

us-gaap:ContractWithCustomerLiabilityCurrent us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:JanssenBiotechInc, us-gaap:Product


Contract
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-31
Value2.0095.768142034394138417.0018.2237.971331
Percentage of ContractWithCustomerLiabilityCurrent100.0100.0100.0124.5197.4209.6234.1234.7234.6100.0100.0100.0100.0100.0
Percentage of Assets0.51.94.59.615.128.926.825.028.15.35.95.49.619.4
Percentage of Assets ptgx:JanssenBiotechInc us-gaap:Product0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Liabilities Current

us-gaap:LiabilitiesCurrent

us-gaap:LiabilitiesCurrent


Liabilities
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value423440383536353033242624293342529.3667.7796.4355.3494.113.126
Percentage of LiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets10.611.612.417.715.727.022.919.922.518.518.816.221.122.726.047.313.39.46.85.216.821.1

Operating Lease Liability Current

us-gaap:OperatingLeaseLiabilityCurrent

us-gaap:OperatingLeaseLiabilityCurrent


Operating
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312019-01-01
Value1567000.01512000.01459000.01406000.01355000.01306000.01256000.01209000.01164000.01120000.01080000.0
Percentage of OperatingLeaseLiabilityCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.40.50.40.60.61.00.80.80.80.80.0

Other Accrued Liabilities Current

us-gaap:OtherAccruedLiabilitiesCurrent

us-gaap:OtherAccruedLiabilitiesCurrent


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value511000.0398000.082000.0128000.036000.0136000.0122000.0210000.022000.096000.095000.0105000.0166000.0328000.0124000.057000.0171000.0108000.0235000.0310000.0259000.085000.0
Percentage of OtherAccruedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.10.10.00.10.00.10.10.10.00.10.10.10.10.20.10.10.20.10.30.31.10.6

Other Liabilities Noncurrent

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:OtherLiabilitiesNoncurrent


Other
Period End2021-06-302021-03-312020-12-312020-09-30
Value121000.0121000.0121000.0170000.0
Percentage of OtherLiabilitiesNoncurrent100.0100.0100.0100.0
Percentage of Assets0.00.00.00.1

Operating Lease Liability Noncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent


Operating
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312019-01-01
Value3691000.04102000.04500000.04885000.05259000.05616000.05961000.06293000.06616000.06924000.07219000.0
Percentage of OperatingLeaseLiabilityNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.91.41.42.22.34.23.84.14.55.20.0

Lessee Operating Lease Liability Payments Due Year Two

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo


Lessee
Period End2020-12-31
Value2059000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearTwo100.0
Percentage of Assets0.6

Lessee Operating Lease Liability Payments Due Year Three

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree


Lessee
Period End2020-12-31
Value2121000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearThree100.0
Percentage of Assets0.7

Lessee Operating Lease Liability Payments Due Year Four

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour


Lessee
Period End2020-12-31
Value895000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearFour100.0
Percentage of Assets0.3

Operating Lease Liability

us-gaap:OperatingLeaseLiability

us-gaap:OperatingLeaseLiability


Operating
Period End2020-12-312019-12-312019-09-302019-06-302019-03-312019-01-01
Value5959000.07217000.07502000.07780000.08044000.08300000.0
Percentage of OperatingLeaseLiability100.0100.0100.0100.0100.0100.0
Percentage of Assets1.84.74.95.36.10.0

Lessee Operating Lease Liability Payments Due

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue


Lessee
Period End2020-12-31
Value7075000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDue100.0
Percentage of Assets2.2

Lessee Operating Lease Liability Undiscounted Excess Amount

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount


Lessee
Period End2020-12-31
Value1116000.0
Percentage of LesseeOperatingLeaseLiabilityUndiscountedExcessAmount100.0
Percentage of Assets0.3

Stockholders Equity

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-312014-12-312013-12-31
Value357259279169167627995841001121231071141205761748797-46.204-27.4-12.621-1.394
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets88.487.086.278.074.446.551.661.756.976.280.783.378.376.873.752.486.690.693.294.8-188.5-184.60.00.0

us-gaap:StockholdersEquity us-gaap:StatementEquityComponents

us-gaap:AccumulatedOtherComprehensiveIncome


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value-0.059-0.0330.028-0.088-0.2080.107-0.221-0.154-0.167-0.189-0.233-0.103-0.086-0.072-0.006-0.245-0.102-0.1-0.046
Percentage of StockholdersEquity-0.0-0.00.0-0.1-0.10.2-0.3-0.2-0.2-0.2-0.2-0.1-0.1-0.1-0.0-0.30.40.83.3
Percentage of Assets-0.0-0.00.0-0.0-0.10.1-0.1-0.1-0.1-0.1-0.2-0.1-0.1-0.0-0.0-0.3-0.70.00.0
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AdditionalPaidInCapital


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value6965675634344243002972952682552532502252232221520.1180.0370.135
Percentage of StockholdersEquity194.8218.7201.5256.3253.7479.2372.5310.1318.1253.5225.1202.2209.6195.3184.2174.1-0.4-0.3-9.7
Percentage of Assets172.2190.3173.6200.0188.8222.6192.3191.2181.1193.3181.6168.4164.1150.0135.7162.10.80.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value-338.651-307.809-283.811-264.925-257.162-237.741-217.661-200.16-183.751-154.577-140.474-126.609-117.874-109.211-101.55-64.593-27.416-12.558-1.483
Percentage of StockholdersEquity-94.7-118.7-101.5-156.2-153.5-379.4-272.2-209.9-217.9-153.3-124.8-102.1-109.5-95.3-84.2-73.8100.199.5106.4
Percentage of Assets-83.8-103.3-87.5-121.9-114.3-176.2-140.5-129.4-124.1-116.9-100.7-85.1-85.7-73.2-62.0-68.7-184.70.00.0
Percentage of Assets us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Additional Paid In Capital Common Stock

us-gaap:AdditionalPaidInCapitalCommonStock

us-gaap:AdditionalPaidInCapitalCommonStock


Additional
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value6965675634344243002972952682552532502252232221561541531521500.1580.118
Percentage of AdditionalPaidInCapitalCommonStock100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets172.2190.3173.6200.0188.8222.6192.3191.2181.1193.3181.6168.4164.1150.0135.7141.5219.5185.8162.1146.70.60.8

Retained Earnings Accumulated Deficit

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:RetainedEarningsAccumulatedDeficit


Retained
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value-338650000.0-307810000.0-283810000.0-264920000.0-257160000.0-237740000.0-217660000.0-200160000.0-183750000.0-154580000.0-140470000.0-126610000.0-117870000.0-109210000.0-101550000.0-98500000.0-93700000.0-78694000.0-64593000.0-53345000.0-46261000.0-27416000.0
Percentage of RetainedEarningsAccumulatedDeficit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-83.8-103.3-87.5-121.9-114.3-176.2-140.5-129.4-124.1-116.9-100.7-85.1-85.7-73.2-62.0-89.2-132.9-95.2-68.7-51.9-188.7-184.7

Accumulated Other Comprehensive Income Loss Net Of Tax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax


Accumulated
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value-59000.0-33000.028000.0-88000.0-208000.0107000.0-221000.0-154000.0-167000.0-189000.0-233000.0-103000.0-86000.0-72000.0-6000.0100000.03000.0-22000.0-245000.0-24000.0-101000.0-102000.0
Percentage of AccumulatedOtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-0.0-0.00.0-0.0-0.10.1-0.1-0.1-0.1-0.1-0.2-0.1-0.1-0.0-0.00.10.0-0.0-0.3-0.0-0.4-0.7

Stock Issued During Period Value New Issues

us-gaap:StockIssuedDuringPeriodValueNewIssues

us-gaap:StockIssuedDuringPeriodValueNewIssues


Stock
Period End2021-06-302020-12-312020-09-302020-06-302019-09-302019-06-302018-09-30
Value123107-0.00310523101.025
Percentage of StockIssuedDuringPeriodValueNewIssues100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.0

us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Stock
Period End2021-06-302020-12-312020-09-302020-06-302019-09-302019-06-302018-09-30
Value123107-0.00310523101.025
Percentage of StockIssuedDuringPeriodValueNewIssues100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.0

us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock

us-gaap:AdditionalPaidInCapital, ptgx:AtMarketingOffering


Stock
Period End2020-12-312020-09-302020-06-302019-12-312019-09-302019-06-30
Value186.368160.02310
Percentage of StockIssuedDuringPeriodValueNewIssues17.5-212266.715.80.0100.0100.0
Percentage of Assets0.00.00.00.00.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital ptgx:AtMarketingOffering0.00.00.00.00.00.0

us-gaap:StockIssuedDuringPeriodValueNewIssues us-gaap:SubsidiarySaleOfStock

ptgx:AtMarketingOffering


Stock
Period End2020-12-312020-09-302020-06-302019-12-312019-09-302019-06-30
Value186.368160.02310
Percentage of StockIssuedDuringPeriodValueNewIssues17.5-212266.715.80.0100.0100.0
Percentage of Assets0.00.00.00.00.00.0
Percentage of Assets ptgx:AtMarketingOffering0.00.00.00.00.00.0

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue


Adjustments
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value3936000.02660000.01967000.01888000.01996000.02048000.02160000.02201000.02013000.01979000.02072000.02017000.01645000.01185000.0
Percentage of AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Adjustments
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value3936000.02660000.01967000.01888000.01996000.02048000.02160000.02201000.02013000.01979000.02072000.02017000.01645000.01185000.0
Percentage of AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value-23.7-28.756-18.867-16.287-21.482-15.848-14.289-14.2463.67-16.662-10.135-9.276-15.398-15.138-14.14940-12.327-10.356
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0463.50.00.0

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value7.773-6.793-74.402-54.122-5.17142-12.554-32.039-13.2254.1084.5499.9179.591-21.8444.752-0.77213-1.25
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0-8.80.00.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value1250.9791267.6691120.3999.77925100.390.479230.0740.53650.0310.0870.374
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.40.00.0

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-30
Value109-34.59333-62.6178627-17.189-20.9481.066-12.156-5.19423-5.713-36.45255400.848-11.117-74.9482
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0455.90.00.00.00.0

Depreciation Depletion And Amortization

us-gaap:DepreciationDepletionAndAmortization

us-gaap:DepreciationDepletionAndAmortization


Depreciation
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
Value185000.0180000.0188000.0182000.0202000.0217000.0202000.0195000.0176000.0130000.0128000.0151000.0170000.078000.0117000.0108000.093000.088000.075000.083000.086000.073000.087000.049000.0
Percentage of DepreciationDepletionAndAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value-23.7-28.756-18.867-16.287-21.482-15.848-14.289-14.2463.67-16.662-10.135-9.276-15.398-15.138-14.14940-12.327-10.356
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0463.50.00.0

Net Income Loss

us-gaap:NetIncomeLoss

us-gaap:NetIncomeLoss


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value-30842000.0-23998000.0-18886000.0-7763000.0-19421000.0-20080000.0-17501000.0-16409000.0-29174000.0-14103000.0-13865000.0-8735000.0-8663000.0-7661000.0-3052000.0-4825000.0-14979000.0-14101000.0-11248000.0-7084000.0-7098000.0-11747000.0-5493000.0-3449000.0-3219000.0-2697000.0
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0-54.90.00.00.00.00.00.00.00.00.00.0

us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value-30842000.0-23998000.0-18886000.0-7763000.0-19421000.0-20080000.0-17501000.0-16409000.0-29174000.0-14103000.0-13865000.0-8735000.0-8663000.0-7661000.0
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Revenues us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Profit Loss

us-gaap:ProfitLoss

us-gaap:ProfitLoss


Profit
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value-30842000.0-23998000.0-18886000.0-7763000.0-19421000.0-20080000.0-17501000.0-16409000.0-29174000.0-14103000.0-13865000.0-8735000.0-8663000.0-7661000.0-3052000.0-4825000.0-14979000.0-14101000.0
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0-54.90.00.0

Share Based Compensation

us-gaap:ShareBasedCompensation

us-gaap:ShareBasedCompensation


Share
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
Value3936000.02660000.01967000.01888000.01996000.02048000.02160000.02201000.02013000.01979000.02072000.02017000.01645000.01185000.01189000.01207000.01002000.0843000.01520000.0448000.0106000.056000.037000.022000.0
Percentage of ShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value7.773-6.793-74.402-54.122-5.17142-12.554-32.039-13.2254.1084.5499.9179.591-21.8444.752-0.77213-1.25
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0-8.80.00.0

Payments To Acquire Property Plant And Equipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment


Payments
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
Value500000.0140000.0125000.075000.0133000.0138000.0218000.0-309000.0892000.0166000.062000.0148000.068000.0208000.056000.0190000.0372000.048000.052000.048000.028000.0251000.0220000.0113000.0
Percentage of PaymentsToAcquirePropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value1250.9791267.6691120.3999.77925100.390.479230.0740.53650.0310.0870.374
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.40.00.0

Effective Income Tax Rate Continuing Operations

us-gaap:EffectiveIncomeTaxRateContinuingOperations

us-gaap:EffectiveIncomeTaxRateContinuingOperations


Effective
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value-0.9-4.82.7660.062-0.009-0.0160.0060.053-0.013
Percentage of EffectiveIncomeTaxRateContinuingOperations100.0100.0100.0100.0100.0100.0100.0100.0100.0

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice


Share
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value15.8414.2711.8711.4711.0410.8711.6411.7711.5111.4512.2312.3712.5412.6711.51
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Unrecognized Tax Benefits

us-gaap:UnrecognizedTaxBenefits

us-gaap:UnrecognizedTaxBenefits


Unrecognized
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Value19169.4665.4142.1310.805
Percentage of UnrecognizedTaxBenefits100.0100.0100.0100.0100.0100.0

Deferred Tax Assets Valuation Allowance

us-gaap:DeferredTaxAssetsValuationAllowance

us-gaap:DeferredTaxAssetsValuationAllowance


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Value715234252310
Percentage of DeferredTaxAssetsValuationAllowance100.0100.0100.0100.0100.0100.0

ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee

ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee


Amortization
Period End2020-12-312020-09-302020-06-302020-03-31
Value137000.00-23000.045000.0
Percentage of AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee100.00.0100.0100.0

ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment

ptgx:JanssenBiotechInc, ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpoint, ptgx:LicenseAndCollaborativeAgreementAmendment


Collaborative
Period End2021-03-312020-09-302020-06-302020-03-31
Value500.00.050
Percentage of CollaborativeArrangementPayableUponEffectivenessOfAmendment100.00.00.0100.0

ptgx:JanssenBiotechInc, ptgx:UpfrontCashPayment, ptgx:AmendedCollaborationAgreementTrancheOne


Collaborative
Period End2021-03-312020-12-312020-09-302020-06-302020-03-31
Value500.00.00.050
Percentage of CollaborativeArrangementPayableUponEffectivenessOfAmendment100.00.00.00.0100.0

ptgx:JanssenBiotechInc, ptgx:UpfrontCashPayment, ptgx:AmendedSecondOptIn


Collaborative
Period End2021-03-312020-12-312020-09-302020-06-302020-03-31
Value500.00.00.050
Percentage of CollaborativeArrangementPayableUponEffectivenessOfAmendment100.00.00.00.0100.0

ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:JanssenBiotechInc, ptgx:PhaseTwoClinicalTrial


Collaborative
Period End2020-09-302020-06-302020-03-31
Value0.00.050
Percentage of CollaborativeArrangementPayableUponEffectivenessOfAmendment0.00.0100.0

ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred us-gaap:CounterpartyName, us-gaap:ProductOrService

ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred

ptgx:JanssenBiotechInc, ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpoint


Collaborative
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
Value020.0019.800.200
Percentage of CollaborativeArrangementPercentageOfDevelopmentCostsIncurred0.0100.00.0100.00.0100.00.00.0

ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement

ptgx:JanssenBiotechInc, ptgx:PN232, us-gaap:SubsequentEvent, ptgx:PhaseOneClinicalTrial


Collaborative
Period End2021-07-27
Value100.0
Percentage of CollaborativeArrangementPercentageOfDevelopmentCostsIncurred0.0

ptgx:JanssenBiotechInc, ptgx:PN235, us-gaap:SubsequentEvent, ptgx:PhaseOneClinicalTrial


Collaborative
Period End2021-07-27
Value50.0
Percentage of CollaborativeArrangementPercentageOfDevelopmentCostsIncurred0.0

ptgx:JanssenBiotechInc, ptgx:PTG200, us-gaap:SubsequentEvent, ptgx:PhaseTwoClinicalTrial


Collaborative
Period End2021-07-27
Value20.0
Percentage of CollaborativeArrangementPercentageOfDevelopmentCostsIncurred0.0

ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred us-gaap:ProductOrService

ptgx:SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpoint


Collaborative
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
Value080.0079.200.8
Percentage of CollaborativeArrangementPercentageOfDevelopmentCostsIncurred0.0400.00.0400.00.0400.0

ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpoint


Collaborative
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
Value080.0079.200.800
Percentage of CollaborativeArrangementPercentageOfDevelopmentCostsIncurred0.0400.00.0400.00.0400.00.00.0

ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred

ptgx:JanssenBiotechInc, ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpoint, ptgx:CollaborationAgreementTrancheFive


Collaborative
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
Value0100.0099.001.000
Percentage of CollaborativeArrangementPercentageOfResearchProgramCostsIncurred0.0100.00.0100.00.0100.00.00.0

ptgx:JanssenBiotechInc, ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpoint, ptgx:CollaborationAgreementTrancheFour


Collaborative
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
Value050.0049.500.500
Percentage of CollaborativeArrangementPercentageOfResearchProgramCostsIncurred0.050.00.050.00.050.00.00.0

ptgx:JanssenBiotechInc, ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpoint, ptgx:CollaborationAgreementTrancheThree


Collaborative
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
Value0100.0099.001.000
Percentage of CollaborativeArrangementPercentageOfResearchProgramCostsIncurred0.0100.00.0100.00.0100.00.00.0

ptgx:ContractWithCustomerAssetAdditions us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:ContractWithCustomerAssetAdditions

ptgx:JanssenBiotechInc, us-gaap:Product


Contract
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value3.0811.570.9371.0822.6931.5095.9551.001281.7260.6531.385
Percentage of ContractWithCustomerAssetAdditions100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:ContractWithCustomerAssetDeduction us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:ContractWithCustomerAssetDeduction

ptgx:JanssenBiotechInc, us-gaap:Product


Contract
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value1.31.292.1485.0121.0194.871270.0043.1972.584
Percentage of ContractWithCustomerAssetDeduction100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:ContractWithCustomerAssetRelatedPartyAdditions us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:ContractWithCustomerAssetRelatedPartyAdditions

ptgx:JanssenBiotechInc, us-gaap:Product


Contract
Period End2020-12-312020-09-302020-06-302020-03-312019-12-31
Value000342000.0-126000.0
Percentage of ContractWithCustomerAssetRelatedPartyAdditions0.00.00.0100.0100.0

ptgx:ContractWithCustomerLiabilityAdditions us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:ContractWithCustomerLiabilityAdditions

ptgx:JanssenBiotechInc, us-gaap:Product


Contract
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value2.9071.0170.4630.5231.1271.856.0151.915340.3423.1490.696
Percentage of ContractWithCustomerLiabilityAdditions100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:ContractWithCustomerLiabilityDeduction us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:ContractWithCustomerLiabilityDeduction

ptgx:JanssenBiotechInc, us-gaap:Product


Contract
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value6.6669.7266.863136.1584.3353.1634.804109602.8965.928
Percentage of ContractWithCustomerLiabilityDeduction100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:DueToRelatedPartyAdditions us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:DueToRelatedPartyAdditions

ptgx:JanssenBiotechInc, us-gaap:Product


Due
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value4573000.04091000.01686000.01074000.0364000.0676000.0242000.0601000.0475000.0150000.0506000.0
Percentage of DueToRelatedPartyAdditions100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:DueToRelatedPartyDeductions us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:DueToRelatedPartyDeductions

ptgx:JanssenBiotechInc, us-gaap:Product


Due
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302018-12-31
Value1031000.00477000.0822000.00391000.0209000.0
Percentage of DueToRelatedPartyDeductions100.00.0100.0100.00.0100.0100.0

ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants

ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants


Expected
Period End2021-01-012020-12-31
Value50.00
Percentage of ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants100.00.0

ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo

ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo


Expected
Period End2021-01-012020-12-31
Value50.00
Percentage of ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo100.00.0

ptgx:IncreaseDecreaseInOperatingLeaseLiability

ptgx:IncreaseDecreaseInOperatingLeaseLiability


Increase
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value491000.0492000.0481000.0477000.032340000.0-31386000.0468000.0463000.0
Percentage of IncreaseDecreaseInOperatingLeaseLiability100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:LicenseAndCollaborationAgreementMaximumCostThatCanBeIncurred us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement

ptgx:LicenseAndCollaborationAgreementMaximumCostThatCanBeIncurred

ptgx:JanssenBiotechInc, ptgx:PTG200, us-gaap:SubsequentEvent, ptgx:PhaseTwoClinicalTrial


License
Period End2021-07-27
Value20
Percentage of LicenseAndCollaborationAgreementMaximumCostThatCanBeIncurred100.0

ptgx:OperatingLeaseRightOfUseAssetAmortization

ptgx:OperatingLeaseRightOfUseAssetAmortization


Operating
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value443000.0444000.0444000.0444000.0443000.0444000.0445000.0444000.0444000.0459000.0
Percentage of OperatingLeaseRightOfUseAssetAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:PotentialQualifiedDiscountFederalIncomeTaxCredit

ptgx:PotentialQualifiedDiscountFederalIncomeTaxCredit


Potential
Period End2021-06-302021-03-31
Value025.0
Percentage of PotentialQualifiedDiscountFederalIncomeTaxCredit0.0100.0

ptgx:ReducedMilestonePaymentAmount us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement

ptgx:ReducedMilestonePaymentAmount

ptgx:JanssenBiotechInc, ptgx:SecondGenerationProducts, us-gaap:SubsequentEvent, ptgx:RestatedAgreementPhase2ClinicalTrial


Reduced
Period End2021-07-27
Value25
Percentage of ReducedMilestonePaymentAmount100.0

ptgx:ResearchAndDevelopmentExpensesReduction ptgx:RevenueSource

ptgx:ResearchAndDevelopmentExpensesReduction

ptgx:SmallBusinessInnovationResearchGrant


Research
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-03-31
Value100000.0100000.0200000.00100000.0300000.0300000.0600000.0358000.0188000.0309000.0229000.064000.061000.00
Percentage of ResearchAndDevelopmentExpensesReduction100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

ptgx:ResearchAndDevelopmentExpensesReduction us-gaap:IncomeTaxAuthorityName

us-gaap:AustralianTaxationOffice


Research
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value1300000.01000000.0600000.0400000.0200000.0300000.0100000.001700000.0620000.0500000.0409000.0463000.0770000.0600000.0493000.0501000.0134000.0
Percentage of ResearchAndDevelopmentExpensesReduction1300.01000.0300.00.0200.0100.033.30.0474.9329.8161.8178.6723.41262.30.00.00.00.0

ptgx:ResearchAndDevelopmentTaxIncentiveRevenueCriteria us-gaap:Range, us-gaap:IncomeTaxAuthorityName

ptgx:ResearchAndDevelopmentTaxIncentiveRevenueCriteria

srt:Maximum, us-gaap:AustralianTaxationOffice


Research
Period End2021-06-302021-03-31
Value0.020
Percentage of ResearchAndDevelopmentTaxIncentiveRevenueCriteria0.0100.0

ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract

ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract


Revenue
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-30
Value2.2656.1895.65136.2173.6472.7194.141-8.1891.562.3536.11711
Percentage of RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:SaleOfStockValueOfSharesAuthorized us-gaap:CounterpartyName

ptgx:SaleOfStockValueOfSharesAuthorized

ptgx:AtMarketOffering


Sale
Period End2021-03-312020-12-312020-09-30
Value31-19.3-6.5
Percentage of SaleOfStockValueOfSharesAuthorized100.0100.0100.0

ptgx:SaleOfStockValueOfSharesAuthorized us-gaap:CounterpartyName, us-gaap:SubsequentEventType

ptgx:AtMarketOffering, us-gaap:SubsequentEvent


Sale
Period End2020-10-14
Value31
Percentage of SaleOfStockValueOfSharesAuthorized0.0

ptgx:SaleOfStockValueOfSharesAuthorized us-gaap:SubsequentEventType, us-gaap:SubsidiarySaleOfStock

us-gaap:SubsequentEvent, ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrants


Sale
Period End2020-10-14
Value94
Percentage of SaleOfStockValueOfSharesAuthorized0.0

ptgx:SaleOfStockValueOfSharesAuthorized us-gaap:SubsidiarySaleOfStock

ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrants


Sale
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-10-31
Value94-19.3-6.51200.0250
Percentage of SaleOfStockValueOfSharesAuthorized295.3100.0100.00.00.00.0

ptgx:SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits

ptgx:SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits


Shares
Period End2021-06-302021-03-31
Value378000.0-189000.0
Percentage of SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits100.0100.0

ptgx:SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Shares
Period End2021-03-31
Value-189000.0
Percentage of SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits100.0

us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments

us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments


Accretion
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
Value-473000.0-348000.0-192000.0-88000.079000.0164000.0197000.0188000.0115000.094000.098000.0-194000.010000.0-120000.0-190000.0-225000.0-150000.0-122000.0-35000.0-10000.010000.0-82000.0
Percentage of AccretionAmortizationOfDiscountsAndPremiumsInvestments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CapitalExpendituresIncurredButNotYetPaid

us-gaap:CapitalExpendituresIncurredButNotYetPaid


Capital
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-06-302018-03-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
Value-34000.097000.058000.06000.016000.05000.0-57000.075000.0-567000.0649000.0-28000.036000.0-36000.0-76000.0118000.021000.0000
Percentage of CapitalExpendituresIncurredButNotYetPaid100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0

us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized

us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized


Contract
Period End2021-06-302020-06-30
Value400000.02100000.0
Percentage of ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized100.0100.0

us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice us-gaap:CounterpartyName, us-gaap:ProductOrService

us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice

ptgx:JanssenBiotechInc, ptgx:LicenseAndCollaborativeRevenue


Contract
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-12-312019-03-31
Value-1.82.314-0.40.70.01.6
Percentage of ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice100.0100.0100.0100.0100.00.0100.0

us-gaap:ContractWithCustomerLiabilityRevenueRecognized

us-gaap:ContractWithCustomerLiabilityRevenueRecognized


Contract
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value1.12.38.52.11.2-2.92.91.61.2-4.45.911108.393-8.261
Percentage of ContractWithCustomerLiabilityRevenueRecognized100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ContractWithCustomerLiabilityRevenueRecognized us-gaap:CounterpartyName, us-gaap:ProductOrService

ptgx:JanssenBiotechInc, ptgx:LicenseAndCollaborativeRevenue


Contract
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-09-302019-03-312018-12-312018-09-302018-03-312017-12-312017-09-30
Value2.15.66.6125.73.64.11.62.36.110118.8
Percentage of ContractWithCustomerLiabilityRevenueRecognized0.0509.1287.0148.2271.4300.0141.4133.3-52.3103.4102.9134.6-106.5

us-gaap:ContractWithCustomerLiabilityRevenueRecognized us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

ptgx:JanssenBiotechInc, ptgx:MilestonePayments, ptgx:SecondGenerationDevelopmentCompound


Contract
Period End2021-03-312020-12-312020-09-302020-06-302020-03-31
Value9.10.3-1.00.07.5
Percentage of ContractWithCustomerLiabilityRevenueRecognized827.313.0-11.80.0625.0

us-gaap:ContractWithCustomerLiabilityRevenueRecognized us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:JanssenBiotechInc, ptgx:LicenseAndCollaborativeAgreementAmendment


Contract
Period End2021-03-312020-12-312020-09-302020-06-302020-03-31
Value5.00.00.00.05.0
Percentage of ContractWithCustomerLiabilityRevenueRecognized454.50.00.00.0416.7

us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction

us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction


Debt
Period End2021-03-31
Value58000.0
Percentage of DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction100.0

us-gaap:DefinedContributionPlanAdministrativeExpenses

us-gaap:DefinedContributionPlanAdministrativeExpenses


Defined
Period End2021-03-31
Value200000.0
Percentage of DefinedContributionPlanAdministrativeExpenses100.0

us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch

us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch


Defined
Period End2021-06-302021-03-31
Value050.0
Percentage of DefinedContributionPlanEmployerMatchingContributionPercentOfMatch0.0100.0

us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount

us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount


Defined
Period End2021-06-302021-03-31
Value03500.0
Percentage of DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount0.0100.0

us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents


Effect
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302017-12-312017-09-302016-12-312016-09-30
Value-51000.0-23000.021000.0123000.0103000.0-72000.0-125000.0100000.0-9000.08000.0-87000.0-110000.0-31000.067000.0-83000.074000.0
Percentage of EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncomeTaxCreditsAndAdjustments

us-gaap:IncomeTaxCreditsAndAdjustments


Income
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value34000.0-8000.01229000.0183000.0773000.0-102000.0-1626000.0180000.0
Percentage of IncomeTaxCreditsAndAdjustments100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties

us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties


Increase
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value4573000.04091000.0656000.01074000.0-113000.0-146000.0242000.0210000.0-401000.0150000.0297000.0488000.0-103000.0379000.0
Percentage of IncreaseDecreaseInAccountsPayableRelatedParties100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInAccountsPayableTrade

us-gaap:IncreaseDecreaseInAccountsPayableTrade


Increase
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value5218000.0-344000.0277000.0-41000.0-840000.0913000.01165000.0-1167000.0-3694000.0696000.0813000.02603000.0
Percentage of IncreaseDecreaseInAccountsPayableTrade100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties

us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties


Increase
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value3081000.01570000.0-363000.0-208000.0-597000.0-3161000.04810000.0-2944000.0-172000.0474000.01000.0-1198000.03062000.0906000.01296000.0
Percentage of IncreaseDecreaseInAccountsReceivableRelatedParties100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInContractWithCustomerLiability

us-gaap:IncreaseDecreaseInContractWithCustomerLiability


Increase
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value-3.759-8.709-6.4-13.136-5.032-2.4852.852-2.88934-1.2220.253-5.232-8.678-9.872-9.987
Percentage of IncreaseDecreaseInContractWithCustomerLiability100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInIncomeTaxesReceivable

us-gaap:IncreaseDecreaseInIncomeTaxesReceivable


Increase
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value931000.0751000.0473000.0239000.0116000.0162000.0-174000.0441000.0332000.0-1059000.0357000.0606000.0460000.0-2009000.0377000.0102000.0
Percentage of IncreaseDecreaseInIncomeTaxesReceivable100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities

us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities


Increase
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
Value2059000.0-673000.02710000.02748000.01082000.0-700000.01879000.0-462000.02734000.0-3053000.0665000.0-2738000.03010000.0974000.01522000.01754000.0158000.01359000.02190000.01003000.0-415000.0617000.0694000.0358000.0
Percentage of IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities


Increase
Period End2020-12-312020-09-30
Value-49000.078000.0
Percentage of IncreaseDecreaseInOtherOperatingLiabilities100.0100.0

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets


Increase
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
Value1478000.0-57000.0-464000.01318000.01054000.0-806000.01234000.0-218000.01398000.0406000.0-591000.0281000.0343000.0-1150000.01367000.0664000.0-112000.0-1586000.01621000.01313000.0-191000.0-943000.01088000.0344000.0
Percentage of IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InvestmentIncomeInterest

us-gaap:InvestmentIncomeInterest


Investment
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
Value97000.0102000.080000.087000.0207000.0526000.0824000.0656000.0604000.0728000.0748000.0654000.0576000.0568000.0461000.0155000.0152000.0172000.0149000.054000.027000.012000.017000.01000.0
Percentage of InvestmentIncomeInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:LossContingencyDamagesSoughtValue us-gaap:CounterpartyName

us-gaap:LossContingencyDamagesSoughtValue

ptgx:ZealandPharma


Loss
Period End2021-06-302021-03-312020-01-23
Value0.01.01.0
Percentage of LossContingencyDamagesSoughtValue0.0100.0100.0

us-gaap:LossContingencyDamagesSoughtValue us-gaap:CounterpartyName, us-gaap:Range, us-gaap:StatementScenario

ptgx:ZealandPharma, srt:Maximum, ptgx:SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartner


Loss
Period End2021-06-302021-03-31
Value0.0100
Percentage of LossContingencyDamagesSoughtValue0.010000.0

us-gaap:LossContingencyDamagesSoughtValue us-gaap:CounterpartyName, us-gaap:StatementScenario

ptgx:ZealandPharma, ptgx:SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartner


Loss
Period End2021-06-302021-03-31
Value0.028
Percentage of LossContingencyDamagesSoughtValue0.02800.0

us-gaap:OperatingLeasePayments

us-gaap:OperatingLeasePayments


Operating
Period End2021-06-302021-03-312020-06-302020-03-31
Value496000.0491000.0481000.0477000.0
Percentage of OperatingLeasePayments100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value-34000.0-33000.0123000.0129000.0-324000.0338000.0-50000.010000.0-19000.015000.0-173000.0-63000.0-68000.0-18000.0-26000.073000.014000.0237000.0
Percentage of OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value-26000.0-61000.0116000.0120000.0-315000.0328000.0-67000.013000.022000.044000.0-130000.0-17000.0-14000.0-66000.0
Percentage of OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent us-gaap:StatementEquityComponents

us-gaap:AccumulatedOtherComprehensiveIncome


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value-26000.0-61000.0116000.0120000.0-315000.0328000.0-67000.013000.022000.044000.0-130000.0-17000.0-14000.0-66000.0
Percentage of OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value8000.0-28000.0-7000.0-9000.09000.0-10000.0-17000.03000.041000.029000.0
Percentage of OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PaymentsOfDebtIssuanceCosts

us-gaap:PaymentsOfDebtIssuanceCosts


Payments
Period End2020-12-312020-09-302020-06-302020-03-31
Value007000.07000.0
Percentage of PaymentsOfDebtIssuanceCosts0.00.0100.0100.0

us-gaap:PaymentsOfStockIssuanceCosts

us-gaap:PaymentsOfStockIssuanceCosts


Payments
Period End2021-03-312017-09-302016-09-30
Value148000.0297000.0-770000.0
Percentage of PaymentsOfStockIssuanceCosts100.0100.0100.0

us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt

us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt


Payments
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value7687132804520496530211912
Percentage of PaymentsToAcquireAvailableForSaleSecuritiesDebt100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProceedsFromDebtNetOfIssuanceCosts

us-gaap:ProceedsFromDebtNetOfIssuanceCosts


Proceeds
Period End2020-12-312020-09-302019-12-312019-09-30
Value186.3850.023
Percentage of ProceedsFromDebtNetOfIssuanceCosts100.0100.00.0100.0

us-gaap:ProceedsFromIssuanceOfCommonStock

us-gaap:ProceedsFromIssuanceOfCommonStock


Proceeds
Period End2020-12-312020-09-302019-12-312019-09-302018-12-31
Value107-0.2110.0230.483
Percentage of ProceedsFromIssuanceOfCommonStock100.0100.00.0100.0100.0

us-gaap:ProceedsFromIssuanceOfCommonStock us-gaap:StatementEquityComponents, us-gaap:SubsequentEventType, us-gaap:SubsidiarySaleOfStock

us-gaap:CommonStock, us-gaap:SubsequentEvent, ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrants


Proceeds
Period End2020-10-14
Value18
Percentage of ProceedsFromIssuanceOfCommonStock0.0

us-gaap:ProceedsFromIssuanceOfCommonStock us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock

us-gaap:CommonStock, ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrants


Proceeds
Period End2020-12-312020-09-30
Value186.4
Percentage of ProceedsFromIssuanceOfCommonStock17.5-3033.2

us-gaap:CommonStock, us-gaap:OverAllotmentOption


Proceeds
Period End2020-12-31
Value107
Percentage of ProceedsFromIssuanceOfCommonStock99.8

us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions

us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions


Proceeds
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value1247000.01316000.0313000.01495000.0585000.0406000.014000.01288000.087000.0390000.02000.0328000.074000.0530000.0218000.0328000.087000.0374000.0
Percentage of ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities

us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities


Proceeds
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
Value848058264063363318262323234.01619136.82.53.90.397.398
Percentage of ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:SaleOfStockConsiderationReceivedOnTransaction us-gaap:SubsidiarySaleOfStock

us-gaap:SaleOfStockConsiderationReceivedOnTransaction

ptgx:UnderwrittenPublicOffering


Sale
Period End2021-06-302020-05-31
Value123105
Percentage of SaleOfStockConsiderationReceivedOnTransaction100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

us-gaap:RestrictedStockUnitsRSU


Share
Period End2021-06-302021-03-31
Value1.4716.81
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue us-gaap:PlanName

ptgx:InducementStockPlan


Share
Period End2020-12-31
Value-0.3
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue0.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue

us-gaap:PerformanceShares


Share
Period End2021-03-31
Value23.57
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:RestrictedStockUnitsRSU


Share
Period End2021-06-302021-03-31
Value023.57
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue0.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue us-gaap:PlanName

ptgx:InducementStockPlan


Share
Period End2020-12-31
Value0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue0.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

us-gaap:PerformanceShares


Share
Period End2021-02-28
Value2600000.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

us-gaap:RestrictedStockUnitsRSU


Share
Period End2021-06-302021-03-31
Value010.13
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue0.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue us-gaap:PlanName

ptgx:InducementStockPlan


Share
Period End2020-12-31
Value0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue0.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum


Share
Period End2021-06-302021-03-312020-06-302020-03-312016-12-31
Value88.890.274.573.80
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum100.0100.0100.0100.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum us-gaap:AwardType

us-gaap:EmployeeStockOption


Share
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value2.485.10.7450.7380.0140.6340.6270.62600.6510.6640.665000.654
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum0.00.01.01.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum


Share
Period End2021-06-302021-03-312020-06-302020-03-312016-12-31
Value88.089.874.372.10
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum100.0100.0100.0100.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum us-gaap:AwardType

us-gaap:EmployeeStockOption


Share
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value084.50.7430.72100.610.620.62200.6120.640.664-0.005-0.0040.644
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum0.00.01.01.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum


Share
Period End2021-06-302021-03-312020-06-302020-03-312016-12-31
Value1.110.970.421.440.0041
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum100.0100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum us-gaap:AwardType

us-gaap:EmployeeStockOption


Share
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value00.40.00420.014400.0190.0220.02580.00050.02980.02980.02730.001700.0198
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum0.00.01.01.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum


Share
Period End2021-06-302021-03-312020-06-302020-03-312016-12-31
Value0.850.110.390.590
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum100.0100.0100.0100.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum us-gaap:AwardType

us-gaap:EmployeeStockOption


Share
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value00.230.00390.005900.01420.01880.024500.02750.02650.0242000.0188
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum0.00.01.01.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue


Share
Period End2021-06-302021-03-312020-12-312017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
Value2.517.290.947.575.046.091.590.68-0.350
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice


Share
Period End2021-06-302021-03-312020-12-31
Value3.088.460.15
Percentage of ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice


Share
Period End2021-06-302021-03-312020-12-31
Value2.5814.08-0.34
Percentage of ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice


Share
Period End2021-06-302021-03-312020-12-31
Value3.5623.411.21
Percentage of ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice100.0100.0100.0

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage us-gaap:AwardType

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage

us-gaap:PerformanceShares


Sharebased
Period End2021-03-31
Value100.0
Percentage of SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage100.0

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent us-gaap:PlanName

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

ptgx:EmployeeStockPurchasePlan2016


Sharebased
Period End2021-06-302021-03-312020-12-31
Value085.00
Percentage of SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent0.0100.00.0

us-gaap:StockIssued1 us-gaap:BalanceSheetLocation, us-gaap:SubsidiarySaleOfStock

us-gaap:StockIssued1

ptgx:AccruedLiabilitiesAndOtherPayables, us-gaap:IPO


Stock
Period End2020-09-30
Value-208000.0
Percentage of StockIssued1100.0

us-gaap:PrepaidExpensesAndOtherCurrentAssets, ptgx:AtMarketingOffering


Stock
Period End2020-09-30
Value0
Percentage of StockIssued1-0.0

us-gaap:PrepaidExpensesAndOtherCurrentAssets, us-gaap:IPO


Stock
Period End2020-09-30
Value0
Percentage of StockIssued1-0.0

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation


Stock
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value1247000.01316000.0313000.01495000.0585000.0406000.014000.01288000.087000.0390000.03000.0327000.073000.0531000.0
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Stock
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value1247000.01316000.0313000.01495000.0585000.0406000.014000.01288000.087000.0390000.03000.0327000.073000.0531000.0
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent

ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent


Accrued
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302015-12-31
Value141411109.4248.9567.2326.426.5935.8867.7817.649108.2776.4375.8644.2994.963.6171.630.976
Percentage of AccruedClinicalAndResearchRelatedExpensesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:AdditionalPaymentObligationToFormerCollaborationPartner us-gaap:ProductOrService, us-gaap:Range, us-gaap:StatementScenario, us-gaap:TypeOfArrangement

ptgx:AdditionalPaymentObligationToFormerCollaborationPartner

ptgx:PhaseThreeClinicalTrailOfPtg300, srt:Maximum, ptgx:EntityRequiredToContinueToMakePayments, ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013


Additional
Period End2020-12-31
Value4500000.0
Percentage of AdditionalPaymentObligationToFormerCollaborationPartner100.0

ptgx:PhaseThreeClinicalTrailOfPtg300, srt:Minimum, ptgx:EntityRequiredToContinueToMakePayments, ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013


Additional
Period End2020-12-31
Value1500000.0
Percentage of AdditionalPaymentObligationToFormerCollaborationPartner33.3

ptgx:PhaseTwoBClinicalTrailOfPtg300, srt:Maximum, ptgx:EntityRequiredToContinueToMakePayments, ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013


Additional
Period End2020-12-31
Value3000000.0
Percentage of AdditionalPaymentObligationToFormerCollaborationPartner66.7

ptgx:PhaseTwoBClinicalTrailOfPtg300, srt:Minimum, ptgx:EntityRequiredToContinueToMakePayments, ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013


Additional
Period End2020-12-31
Value1000000.0
Percentage of AdditionalPaymentObligationToFormerCollaborationPartner22.2

ptgx:CashCashEquivalentsAndMarketableSecuritiesCarryingValue

ptgx:CashCashEquivalentsAndMarketableSecuritiesCarryingValue


Cash
Period End2021-06-30
Value380
Percentage of CashCashEquivalentsAndMarketableSecuritiesCarryingValue100.0

ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost

ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value373275304195203116131127
Percentage of CashEquivalentsAndMarketableSecuritiesAmortizedCost100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost us-gaap:CashAndCashEquivalents

us-gaap:CommercialPaper


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value14198654114394459
Percentage of CashEquivalentsAndMarketableSecuritiesAmortizedCost37.935.821.721.37.134.133.646.8

us-gaap:MoneyMarketFunds


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value123342745139451225
Percentage of CashEquivalentsAndMarketableSecuritiesAmortizedCost33.012.79.023.268.339.39.819.9

ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost us-gaap:InvestmentType

ptgx:SupranationalAndSovereignGovernmentSecurities


Cash
Period End2021-06-302021-03-31
Value6.0456.061
Percentage of CashEquivalentsAndMarketableSecuritiesAmortizedCost1.62.2

ptgx:UsTreasuryAndAgencySecurities


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value32691838744174033
Percentage of CashEquivalentsAndMarketableSecuritiesAmortizedCost8.625.160.244.622.115.131.026.2

us-gaap:CorporateDebtSecurities


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value706727214.89313338.997
Percentage of CashEquivalentsAndMarketableSecuritiesAmortizedCost18.924.39.111.02.411.525.67.1

ptgx:CashEquivalentsAndMarketableSecuritiesFairValue

ptgx:CashEquivalentsAndMarketableSecuritiesFairValue


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value372275304195203116131127
Percentage of CashEquivalentsAndMarketableSecuritiesFairValue100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:CashEquivalentsAndMarketableSecuritiesFairValue us-gaap:CashAndCashEquivalents

us-gaap:CommercialPaper


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value14198654114394459
Percentage of CashEquivalentsAndMarketableSecuritiesFairValue37.935.821.721.37.134.133.646.8

us-gaap:MoneyMarketFunds


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value123342745139451225
Percentage of CashEquivalentsAndMarketableSecuritiesFairValue33.012.79.023.268.339.39.819.9

ptgx:CashEquivalentsAndMarketableSecuritiesFairValue us-gaap:InvestmentType

ptgx:SupranationalAndSovereignGovernmentSecurities


Cash
Period End2021-06-302021-03-31
Value6.0446.059
Percentage of CashEquivalentsAndMarketableSecuritiesFairValue1.62.2

ptgx:UsTreasuryAndAgencySecurities


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value32691838744174033
Percentage of CashEquivalentsAndMarketableSecuritiesFairValue8.625.160.244.622.115.131.026.2

us-gaap:CorporateDebtSecurities


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value706627214.89813338.989
Percentage of CashEquivalentsAndMarketableSecuritiesFairValue18.924.39.111.02.411.525.67.1

ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain

ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Value8000.09000.012000.013000.019000.029000.027000.0
Percentage of CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain100.0100.0100.0100.0100.0100.0100.0

ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain us-gaap:CashAndCashEquivalents

us-gaap:CommercialPaper


Cash
Period End2021-06-302020-06-302020-03-312019-12-31
Value1000.06000.03000.02000.0
Percentage of CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain12.531.610.37.4

ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain us-gaap:InvestmentType

ptgx:UsTreasuryAndAgencySecurities


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Value2000.06000.010000.010000.08000.024000.014000.0
Percentage of CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain25.066.783.376.942.182.851.9

us-gaap:CorporateDebtSecurities


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Value5000.03000.02000.03000.05000.02000.011000.0
Percentage of CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain62.533.316.723.126.36.940.7

ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss

ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value26000.035000.010000.04000.01000.020000.08000.037000.0
Percentage of CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss100.0100.0100.0100.0100.0100.0100.0100.0

ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss us-gaap:CashAndCashEquivalents

us-gaap:CommercialPaper


Cash
Period End2021-06-302021-03-312020-12-312020-03-312019-12-31
Value4000.04000.03000.016000.04000.0
Percentage of CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss15.411.430.080.050.0

ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss us-gaap:InvestmentType

ptgx:SupranationalAndSovereignGovernmentSecurities


Cash
Period End2021-06-302021-03-31
Value1000.02000.0
Percentage of CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss3.85.7

ptgx:UsTreasuryAndAgencySecurities


Cash
Period End2021-06-302020-12-312020-06-302020-03-312019-12-312018-12-31
Value8000.03000.01000.01000.02000.029000.0
Percentage of CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss30.830.0100.05.025.078.4

us-gaap:CorporateDebtSecurities


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-03-312019-12-312018-12-31
Value13000.029000.04000.04000.03000.02000.08000.0
Percentage of CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss50.082.940.0100.015.025.021.6

ptgx:DeferredTaxAssetsOperatingLeaseLiability

ptgx:DeferredTaxAssetsOperatingLeaseLiability


Deferred
Period End2020-12-312019-12-31
Value1252000.01516000.0
Percentage of DeferredTaxAssetsOperatingLeaseLiability100.0100.0

ptgx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther

ptgx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value5332000.05454000.02455000.01322000.0908000.0
Percentage of DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther100.0100.0100.0100.0100.0

ptgx:LicenseAndCollaborationAgreementDevelopmentExpensesObligationEliminated us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement

ptgx:LicenseAndCollaborationAgreementDevelopmentExpensesObligationEliminated

ptgx:JanssenBiotechInc, ptgx:SecondGenerationProducts, us-gaap:SubsequentEvent, ptgx:PhaseThreeClinicalTrial


License
Period End2021-07-27
Value5.0
Percentage of LicenseAndCollaborationAgreementDevelopmentExpensesObligationEliminated100.0

ptgx:JanssenBiotechInc, ptgx:SecondGenerationProducts, us-gaap:SubsequentEvent, ptgx:PhaseTwoClinicalTrial


License
Period End2021-07-27
Value25
Percentage of LicenseAndCollaborationAgreementDevelopmentExpensesObligationEliminated500.0

ptgx:LicenseAndCollaborationAgreementPercentageOfDevelopmentExpensesObligationEliminated us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement

ptgx:LicenseAndCollaborationAgreementPercentageOfDevelopmentExpensesObligationEliminated

ptgx:JanssenBiotechInc, ptgx:SecondGenerationProducts, us-gaap:SubsequentEvent, ptgx:PhaseThreeClinicalTrial


License
Period End2021-07-27
Value50.0
Percentage of LicenseAndCollaborationAgreementPercentageOfDevelopmentExpensesObligationEliminated100.0

ptgx:JanssenBiotechInc, ptgx:SecondGenerationProducts, us-gaap:SubsequentEvent, ptgx:PhaseTwoClinicalTrial


License
Period End2021-07-27
Value20.0
Percentage of LicenseAndCollaborationAgreementPercentageOfDevelopmentExpensesObligationEliminated40.0

ptgx:OperatingLeaseAdditionalBaseRent us-gaap:SubsequentEventType

ptgx:OperatingLeaseAdditionalBaseRent

us-gaap:SubsequentEvent


Operating
Period End2021-07-02
Value1500000.0
Percentage of OperatingLeaseAdditionalBaseRent100.0

ptgx:OperatingLossCarryforwardsNoExpiration us-gaap:IncomeTaxAuthority

ptgx:OperatingLossCarryforwardsNoExpiration

us-gaap:DomesticCountry


Operating
Period End2020-12-31
Value144
Percentage of OperatingLossCarryforwardsNoExpiration100.0

ptgx:PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation us-gaap:CounterpartyName, us-gaap:StatementScenario

ptgx:PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation

ptgx:ZealandPharma, ptgx:SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartner


Potential
Period End2020-12-31
Value28
Percentage of PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation100.0

ptgx:PotentialMilestonePaymentsOnContractualObligation us-gaap:ProductOrService, us-gaap:Range, us-gaap:TypeOfArrangement

ptgx:PotentialMilestonePaymentsOnContractualObligation

ptgx:PTG300, srt:Maximum, ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013


Potential
Period End2020-09-30
Value128
Percentage of PotentialMilestonePaymentsOnContractualObligation100.0

ptgx:PotentialSalesMilestonePaymentsOnContractualObligation us-gaap:CounterpartyName, us-gaap:StatementScenario

ptgx:PotentialSalesMilestonePaymentsOnContractualObligation

ptgx:ZealandPharma, ptgx:SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartner


Potential
Period End2020-12-31
Value100
Percentage of PotentialSalesMilestonePaymentsOnContractualObligation100.0

ptgx:PrepaidManufacturingOfClinicalMaterials

ptgx:PrepaidManufacturingOfClinicalMaterials


Prepaid
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Value3517000.02567000.0686000.02324000.02488000.01253000.0
Percentage of PrepaidManufacturingOfClinicalMaterials100.0100.0100.0100.0100.0100.0

ptgx:ReimbursementForServicesPerformed us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

ptgx:ReimbursementForServicesPerformed

ptgx:JanssenBiotechInc, ptgx:LicenseAndCollaborativeRevenue, ptgx:PhaseTwoClinicalTrial


Reimbursement
Period End2021-06-30
Value17
Percentage of ReimbursementForServicesPerformed100.0

ptgx:JanssenBiotechInc, ptgx:MilestonePayments, ptgx:SecondGenerationDevelopmentCompound


Reimbursement
Period End2021-06-30
Value9.6
Percentage of ReimbursementForServicesPerformed53.6

ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement

ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable

ptgx:JanssenBiotechInc, ptgx:SecondGenerationProducts, us-gaap:SubsequentEvent, ptgx:PhaseTwoClinicalTrial


Research
Period End2021-07-27
Value50
Percentage of ResearchAndCollaborationAgreementDevelopmentMilestonePayable100.0

ptgx:ResearchAndCollaborationAgreementDevelopmentMilestonePayable us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

ptgx:JanssenBiotechInc, ptgx:LicenseAndCollaborativeRevenue, ptgx:EstimatedVariableConsideration


Research
Period End2021-06-30
Value7.5
Percentage of ResearchAndCollaborationAgreementDevelopmentMilestonePayable0.0

ptgx:JanssenBiotechInc, ptgx:MaintenanceFee, ptgx:LicenseAndCollaborativeAgreementAmendment


Research
Period End2021-06-30
Value50
Percentage of ResearchAndCollaborationAgreementDevelopmentMilestonePayable0.0

ptgx:JanssenBiotechInc, ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpoint, ptgx:LicenseAndCollaborativeAgreementAmendment


Research
Period End2021-06-30
Value50
Percentage of ResearchAndCollaborationAgreementDevelopmentMilestonePayable0.0

ptgx:JanssenBiotechInc, ptgx:UpfrontCashPayment, ptgx:AmendedSecondOptIn


Research
Period End2021-06-30
Value50
Percentage of ResearchAndCollaborationAgreementDevelopmentMilestonePayable0.0

us-gaap:AccruedEmployeeBenefitsCurrent

us-gaap:AccruedEmployeeBenefitsCurrent


Accrued
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value3780000.01775000.06413000.04371000.02808000.01731000.04637000.03480000.02460000.01703000.02726000.02410000.02080000.01267000.02718000.01611000.01338000.0847000.01420000.01074000.0695000.0754000.0
Percentage of AccruedEmployeeBenefitsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AccruedProfessionalFeesCurrent

us-gaap:AccruedProfessionalFeesCurrent


Accrued
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-06-302015-12-31
Value829000.0723000.0668000.0857000.0649000.0725000.0301000.0376000.0529000.0425000.061000.0332000.0441000.0486000.0267000.0709000.0669000.0732000.0115000.0735000.064000.0
Percentage of AccruedProfessionalFeesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AreaOfLand us-gaap:SubsequentEventType

us-gaap:AreaOfLand

us-gaap:SubsequentEvent


Area
Period End2021-07-02
Value15000.0
Percentage of AreaOfLand100.0

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:AssetsFairValueDisclosure

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value1233427451394512163814254811
Percentage of AssetsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value2492402761506470118115828910210573
Percentage of AssetsFairValueDisclosure203.2689.51006.7331.646.3154.2916.0705.5211.7600.2402.2215.7655.7

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:MoneyMarketFunds


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value1233427451394512163814254811
Percentage of AssetsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, ptgx:SupranationalAndSovereignGovernmentSecurities


Assets
Period End2021-06-302021-03-31
Value6.0446.059
Percentage of AssetsFairValueDisclosure4.917.3

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, ptgx:UsTreasuryAndAgencySecurities


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value32691838744174033
Percentage of AssetsFairValueDisclosure26.1198.1666.7192.332.438.4314.8131.5

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, us-gaap:CommercialPaper


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value141986541143944403654595810
Percentage of AssetsFairValueDisclosure115.0282.3239.791.910.586.7341.6249.594.0368.5235.3120.295.6

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring, us-gaap:CorporateDebtSecurities


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value706627214.89813338.989
Percentage of AssetsFairValueDisclosure57.2191.7100.447.33.529.1259.735.4

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value37227530419520311613113112110312715385
Percentage of AssetsFairValueDisclosure303.2789.51106.7431.6146.3254.21016.0805.5311.7700.2502.2315.7755.7

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType

us-gaap:FairValueMeasurementsRecurring, ptgx:SupranationalAndSovereignGovernmentSecurities


Assets
Period End2021-06-302021-03-31
Value6.0446.059
Percentage of AssetsFairValueDisclosure4.917.3

us-gaap:FairValueMeasurementsRecurring, ptgx:UsTreasuryAndAgencySecurities


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value32691838744174033
Percentage of AssetsFairValueDisclosure26.1198.1666.7192.332.438.4314.8131.5

us-gaap:FairValueMeasurementsRecurring, us-gaap:CommercialPaper


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value141986541143944403654595810
Percentage of AssetsFairValueDisclosure115.0282.3239.791.910.586.7341.6249.594.0368.5235.3120.295.6

us-gaap:FairValueMeasurementsRecurring, us-gaap:CorporateDebtSecurities


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-31
Value706627214.89813338.989
Percentage of AssetsFairValueDisclosure57.2191.7100.447.33.529.1259.735.4

us-gaap:FairValueMeasurementsRecurring, us-gaap:MoneyMarketFunds


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value1233427451394512163814254811
Percentage of AssetsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CashEquivalentsAtCarryingValue

us-gaap:CashEquivalentsAtCarryingValue


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value1857911379141583144666180846168104479.2367.5911895122.136
Percentage of CashEquivalentsAtCarryingValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CommonStockValueOutstanding us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock

us-gaap:CommonStockValueOutstanding

us-gaap:CommonStock, ptgx:CommonStockPreferredStockAndCertainDebtSecurities


Common
Period End2020-09-30
Value72
Percentage of CommonStockValueOutstanding100.0

us-gaap:ContractWithCustomerAssetNet us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

us-gaap:ContractWithCustomerAssetNet

ptgx:JanssenBiotechInc, us-gaap:Product


Contract
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-31
Value7.0773.9962.4262.7892.9972.4525.9551.0194.8893.7642.0424.5865.7851.816
Percentage of ContractWithCustomerAssetNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:ContractWithCustomerLiabilityNoncurrent

us-gaap:ContractWithCustomerLiabilityNoncurrent


Contract
Period End2020-09-302020-06-302020-03-312019-12-312019-09-302019-06-30
Value4.1121620232223
Percentage of ContractWithCustomerLiabilityNoncurrent100.0100.0100.0100.0100.0100.0

us-gaap:DebtInstrumentInterestRateEffectivePercentage

us-gaap:DebtInstrumentInterestRateEffectivePercentage


Debt
Period End2020-12-312019-12-31
Value9.859.81
Percentage of DebtInstrumentInterestRateEffectivePercentage100.0100.0

us-gaap:DeferredIncomeTaxLiabilities

us-gaap:DeferredIncomeTaxLiabilities


Deferred
Period End2020-12-312019-12-31
Value1040000.01269000.0
Percentage of DeferredIncomeTaxLiabilities100.0100.0

us-gaap:DeferredTaxAssetsGross

us-gaap:DeferredTaxAssetsGross


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Value725534252310
Percentage of DeferredTaxAssetsGross100.0100.0100.0100.0100.0100.0

us-gaap:DeferredTaxAssetsOperatingLossCarryforwards

us-gaap:DeferredTaxAssetsOperatingLossCarryforwards


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Value50392721219.513
Percentage of DeferredTaxAssetsOperatingLossCarryforwards100.0100.0100.0100.0100.0100.0

us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment

us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value1237000.0318000.0269000.0339000.0419000.0
Percentage of DeferredTaxAssetsPropertyPlantAndEquipment100.0100.0100.0100.0100.0

us-gaap:DeferredTaxAssetsTaxCreditCarryforwards

us-gaap:DeferredTaxAssetsTaxCreditCarryforwards


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Value148.0384.272.5441.1430.285
Percentage of DeferredTaxAssetsTaxCreditCarryforwards100.0100.0100.0100.0100.0100.0

us-gaap:DeferredTaxLiabilitiesLeasingArrangements

us-gaap:DeferredTaxLiabilitiesLeasingArrangements


Deferred
Period End2020-12-312019-12-31
Value1040000.01269000.0
Percentage of DeferredTaxLiabilitiesLeasingArrangements100.0100.0

us-gaap:DueFromRelatedPartiesCurrent

us-gaap:DueFromRelatedPartiesCurrent


Due
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302017-12-31
Value7077000.03996000.02426000.02789000.02997000.03594000.06755000.01945000.04889000.05061000.04587000.04586000.01816000.0
Percentage of DueFromRelatedPartiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DueToRelatedPartiesCurrent

us-gaap:DueToRelatedPartiesCurrent


Due
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value116.8232.7322.0771.0031.1161.2621.020.811.2111.0610.764
Percentage of DueToRelatedPartiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DueToRelatedPartiesCurrent us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:JanssenBiotechInc, us-gaap:Product


Due
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-30
Value116.8232.7322.0771.0031.1161.2621.020.811.2111.0610.7640.276
Percentage of DueToRelatedPartiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized


Employee
Period End2021-06-302021-03-312020-12-312020-09-30
Value46421614
Percentage of EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized100.0100.0100.0100.0

us-gaap:GrantsReceivable ptgx:RevenueSource

us-gaap:GrantsReceivable

ptgx:SmallBusinessInnovationResearchGrant


Grants
Period End2021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-31
Value100000.0100000.0300000.0304000.0700000.0358000.0188000.0309000.058000.0
Percentage of GrantsReceivable100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncomeTaxesReceivable

us-gaap:IncomeTaxesReceivable


Income
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value2778000.01823000.01084000.0535000.0276000.0153000.0173000.01421000.01876000.01429000.01600000.03000000.02500000.01347000.02241000.0
Percentage of IncomeTaxesReceivable100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncomeTaxesReceivable us-gaap:IncomeTaxAuthority, us-gaap:IncomeTaxAuthorityName

ptgx:OverseasFindings, us-gaap:AustralianTaxationOffice


Income
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value3700000.02400000.01400000.0800000.0400000.0300000.02000000.0300000.02000000.02600000.02000000.01700000.03100000.0
Percentage of IncomeTaxesReceivable133.2131.7129.2149.5144.9196.10.0173.4140.7138.6140.0126.2138.3

us-gaap:InterestPayableCurrent

us-gaap:InterestPayableCurrent


Interest
Period End2020-09-302020-03-312019-12-31
Value2000.068000.068000.0
Percentage of InterestPayableCurrent100.0100.0100.0

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths


Lessee
Period End2020-12-31
Value2000000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths100.0

us-gaap:MarketableSecuritiesNoncurrent

us-gaap:MarketableSecuritiesNoncurrent


Marketable
Period End2021-06-302021-03-312020-12-312020-09-30
Value266.2542.06.025
Percentage of MarketableSecuritiesNoncurrent100.0100.0100.0100.0

us-gaap:OperatingLossCarryforwards us-gaap:IncomeTaxAuthority

us-gaap:OperatingLossCarryforwards

us-gaap:DomesticCountry


Operating
Period End2020-12-312019-12-312018-12-312016-12-31
Value22216410948
Percentage of OperatingLossCarryforwards100.0100.0100.0100.0

us-gaap:StateAndLocalJurisdiction


Operating
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value214151976837
Percentage of OperatingLossCarryforwards96.292.189.00.078.5

us-gaap:OperatingLossCarryforwards us-gaap:IncomeTaxAuthorityName

us-gaap:AustralianTaxationOffice


Operating
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value3.7139.8109.2
Percentage of OperatingLossCarryforwards1.78.09.00.019.2

us-gaap:OtherAccountsPayableAndAccruedLiabilities

us-gaap:OtherAccountsPayableAndAccruedLiabilities


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value2017181512111210108.713111013109.5468.2416.7276.6475.2723.0142.6691.879
Percentage of OtherAccountsPayableAndAccruedLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OtherPrepaidExpenseCurrent

us-gaap:OtherPrepaidExpenseCurrent


Other
Period End2020-12-312019-12-312018-12-312017-12-31
Value1009000.01057000.01005000.0936000.0
Percentage of OtherPrepaidExpenseCurrent100.0100.0100.0100.0

us-gaap:OtherReceivablesNetCurrent

us-gaap:OtherReceivablesNetCurrent


Other
Period End2020-12-312019-12-312018-12-312017-12-31
Value311000.0744000.0495000.0135000.0
Percentage of OtherReceivablesNetCurrent100.0100.0100.0100.0

us-gaap:PrepaidInsurance

us-gaap:PrepaidInsurance


Prepaid
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value1440000.01161000.0438000.0378000.0408000.0
Percentage of PrepaidInsurance100.0100.0100.0100.0100.0

us-gaap:RestrictedCashNoncurrent

us-gaap:RestrictedCashNoncurrent


Restricted
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-30
Value225000.0225000.0450000.0450000.0450000.0450000.0450000.0450000.0450000.0450000.0450000.0450000.0450000.0450000.0450000.0450000.0450000.0450000.0000
Percentage of RestrictedCashNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0

us-gaap:RestrictedCashNoncurrent us-gaap:CreditFacility

us-gaap:LetterOfCredit


Restricted
Period End2021-06-302021-03-312020-12-31
Value200000.0200000.0500000.0
Percentage of RestrictedCashNoncurrent88.988.9111.1

us-gaap:RevenueRemainingPerformanceObligation

us-gaap:RevenueRemainingPerformanceObligation


Revenue
Period End2021-03-312020-12-312020-06-302020-03-312019-12-312018-12-312017-12-31
Value96981131131126053
Percentage of RevenueRemainingPerformanceObligation100.0100.0100.0100.0100.0100.0100.0

us-gaap:RevenueRemainingPerformanceObligation us-gaap:CounterpartyName, us-gaap:ProductOrService

ptgx:JanssenBiotechInc, ptgx:LicenseAndCollaborativeRevenue


Revenue
Period End2021-06-302021-03-312020-09-302020-06-302020-03-31
Value959699113113
Percentage of RevenueRemainingPerformanceObligation0.0100.00.0100.0100.0

us-gaap:RevenueRemainingPerformanceObligation us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

ptgx:JanssenBiotechInc, us-gaap:Product


Revenue
Period End2020-12-312019-12-312018-12-31
Value9811260
Percentage of RevenueRemainingPerformanceObligation100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

us-gaap:RestrictedStockUnitsRSU


Share
Period End2021-06-302021-03-312020-12-31
Value19.3119.289.31
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue us-gaap:PlanName

ptgx:InducementStockPlan


Share
Period End2020-12-312020-09-302019-12-31
Value9.319.2410.08
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue100.00.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice


Share
Period End2021-06-302021-03-312020-12-312020-09-30
Value12.3912.2212.112.15
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue


Share
Period End2021-06-302021-03-312020-12-312020-09-302019-12-31
Value1736640382.4
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue100.0100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue


Share
Period End2021-06-302021-03-312020-12-312020-09-30
Value173664038
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice


Share
Period End2021-06-302021-03-312020-12-312020-09-30
Value15.8414.2711.8711.47
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice100.0100.0100.0100.0

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1


Sharebased
Period End2021-06-302021-03-312020-12-312020-09-30
Value96372219
Percentage of SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1100.0100.0100.0100.0

us-gaap:SharesIssuedPricePerShare us-gaap:StatementEquityComponents

us-gaap:SharesIssuedPricePerShare

us-gaap:CommonStock


Shares
Period End2020-12-312020-05-312017-10-31
Value21.014.017.0
Percentage of SharesIssuedPricePerShare100.0100.0100.0

us-gaap:SharesIssuedPricePerShare us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock

us-gaap:CommonStock, us-gaap:OverAllotmentOption


Shares
Period End2020-12-312020-05-312017-11-302016-09-30
Value21.014.017.012.0
Percentage of SharesIssuedPricePerShare100.0100.00.00.0

us-gaap:TaxCreditCarryforwardAmount us-gaap:IncomeTaxAuthority, us-gaap:TaxCreditCarryforward

us-gaap:TaxCreditCarryforwardAmount

us-gaap:DomesticCountry, us-gaap:Research


Tax
Period End2020-12-312019-12-312018-12-31
Value126.64.0
Percentage of TaxCreditCarryforwardAmount100.0100.0100.0

us-gaap:StateAndLocalJurisdiction, us-gaap:Research


Tax
Period End2020-12-312019-12-312018-12-312017-12-31
Value4.83.32.21.3
Percentage of TaxCreditCarryforwardAmount39.050.055.00.0

us-gaap:TaxCreditCarryforwardAmount us-gaap:IncomeTaxAuthorityName, us-gaap:TaxCreditCarryforward

us-gaap:AustralianTaxationOffice, us-gaap:Research


Tax
Period End2020-12-312019-12-31
Value3.63.5
Percentage of TaxCreditCarryforwardAmount29.353.0

us-gaap:WarrantsAndRightsOutstanding us-gaap:SubsidiarySaleOfStock

us-gaap:WarrantsAndRightsOutstanding

ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrants


Warrants
Period End2021-06-30
Value94
Percentage of WarrantsAndRightsOutstanding100.0

ptgx:FinancingFacilitySalesAgreement


Warrants
Period End2021-06-30
Value31
Percentage of WarrantsAndRightsOutstanding33.9

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)
Allocated Share Based Compensation Expenseus-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
('ptgx:JanssenBiotechInc', 'ptgx:LicenseAndCollaborativeRevenue', None)
Revenue From Contract With Customer Including Assessed Taxus-gaap: Counterparty Name, us-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType
(None,)
Property Plant And Equipment Grossus-gaap: Property Plant And Equipment By Type
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components